

GLOBAL JOURNAL

OF MEDICAL RESEARCH: C

Microbiology & Pathology

Pneumoniae to Oxacillin

Ofloxacin and Rifampicin

Highlights

Diagnosis of *Mycoplasma*

Assessment of Clinicians

Discovering Thoughts, Inventing Future

VOLUME 15

ISSUE 4

VERSION 1.0



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY

VOLUME 15 ISSUE 4 (VER. 1.0)

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical
Research . 2015.

All rights reserved.

This is a special issue published in version 1.0
of "Global Journal of Medical Research." By
Global Journals Inc.

All articles are open access articles distributed
under "Global Journal of Medical Research"

Reading License, which permits restricted use.
Entire contents are copyright by of "Global
Journal of Medical Research" unless
otherwise noted on specific articles.

No part of this publication may be reproduced
or transmitted in any form or by any means,
electronic or mechanical, including
photocopy, recording, or any information
storage and retrieval system, without written
permission.

The opinions and statements made in this
book are those of the authors concerned.
Ultraculture has not verified and neither
confirms nor denies any of the foregoing and
no warranty or fitness is implied.

Engage with the contents herein at your own
risk.

The use of this journal, and the terms and
conditions for our providing information, is
governed by our Disclaimer, Terms and
Conditions and Privacy Policy given on our
website [http://globaljournals.us/terms-and-condition/
menu-id-1463/](http://globaljournals.us/terms-and-condition/menu-id-1463/)

By referring / using / reading / any type of
association / referencing this journal, this
signifies and you acknowledge that you have
read them and that you accept and will be
bound by the terms thereof.

All information, journals, this journal,
activities undertaken, materials, services and
our website, terms and conditions, privacy
policy, and this journal is subject to change
anytime without any prior notice.

Incorporation No.: 0423089
License No.: 42125/022010/1186
Registration No.: 430374
Import-Export Code: 1109007027
Employer Identification Number (EIN):
USA Tax ID: 98-0673427

Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; **Reg. Number: 0423089**)
*Sponsors: Open Association of Research Society
Open Scientific Standards*

Publisher's Headquarters office

Global Journals Headquarters
301st Edgewater Place Suite, 100 Edgewater Dr.-Pl,
Wakefield MASSACHUSETTS, Pin: 01880,
United States of America
*USA Toll Free: +001-888-839-7392
USA Toll Free Fax: +001-888-839-7392*

Offset Typesetting

Global Journals Incorporated
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,
Pin: CR9 2ER, United Kingdom

Packaging & Continental Dispatching

Global Journals
E-3130 Sudama Nagar, Near Gopur Square,
Indore, M.P., Pin:452009, India

Find a correspondence nodal officer near you

To find nodal officer of your country, please
email us at local@globaljournals.org

eContacts

Press Inquiries: press@globaljournals.org
Investor Inquiries: investors@globaljournals.org
Technical Support: technology@globaljournals.org
Media & Releases: media@globaljournals.org

Pricing (Including by Air Parcel Charges):

For Authors:

22 USD (B/W) & 50 USD (Color)
Yearly Subscription (Personal & Institutional):
200 USD (B/W) & 250 USD (Color)

INTEGRATED EDITORIAL BOARD
(COMPUTER SCIENCE, ENGINEERING, MEDICAL, MANAGEMENT, NATURAL
SCIENCE, SOCIAL SCIENCE)

John A. Hamilton, "Drew" Jr.,
Ph.D., Professor, Management
Computer Science and Software
Engineering
Director, Information Assurance
Laboratory
Auburn University

Dr. Henry Hexmoor
IEEE senior member since 2004
Ph.D. Computer Science, University at
Buffalo
Department of Computer Science
Southern Illinois University at Carbondale

Dr. Osman Balci, Professor
Department of Computer Science
Virginia Tech, Virginia University
Ph.D. and M.S. Syracuse University,
Syracuse, New York
M.S. and B.S. Bogazici University,
Istanbul, Turkey

Yogita Bajpai
M.Sc. (Computer Science), FICCT
U.S.A. Email:
yogita@computerresearch.org

Dr. T. David A. Forbes
Associate Professor and Range
Nutritionist
Ph.D. Edinburgh University - Animal
Nutrition
M.S. Aberdeen University - Animal
Nutrition
B.A. University of Dublin- Zoology

Dr. Wenying Feng
Professor, Department of Computing &
Information Systems
Department of Mathematics
Trent University, Peterborough,
ON Canada K9J 7B8

Dr. Thomas Wischgoll
Computer Science and Engineering,
Wright State University, Dayton, Ohio
B.S., M.S., Ph.D.
(University of Kaiserslautern)

Dr. Abdurrahman Arslanyilmaz
Computer Science & Information Systems
Department
Youngstown State University
Ph.D., Texas A&M University
University of Missouri, Columbia
Gazi University, Turkey

Dr. Xiaohong He
Professor of International Business
University of Quinnipiac
BS, Jilin Institute of Technology; MA, MS,
PhD,. (University of Texas-Dallas)

Burcin Becerik-Gerber
University of Southern California
Ph.D. in Civil Engineering
DDes from Harvard University
M.S. from University of California, Berkeley
& Istanbul University

Dr. Bart Lambrecht

Director of Research in Accounting and Finance
Professor of Finance
Lancaster University Management School
BA (Antwerp); MPhil, MA, PhD
(Cambridge)

Dr. Carlos García Pont

Associate Professor of Marketing
IESE Business School, University of Navarra
Doctor of Philosophy (Management),
Massachusetts Institute of Technology (MIT)
Master in Business Administration, IESE,
University of Navarra
Degree in Industrial Engineering,
Universitat Politècnica de Catalunya

Dr. Fotini Labropulu

Mathematics - Luther College
University of Regina
Ph.D., M.Sc. in Mathematics
B.A. (Honors) in Mathematics
University of Windsor

Dr. Lynn Lim

Reader in Business and Marketing
Roehampton University, London
BCom, PGDip, MBA (Distinction), PhD,
FHEA

Dr. Mihaly Mezei

ASSOCIATE PROFESSOR
Department of Structural and Chemical
Biology, Mount Sinai School of Medical
Center
Ph.D., Eötvös Loránd University
Postdoctoral Training,
New York University

Dr. Söhnke M. Bartram

Department of Accounting and Finance
Lancaster University Management School
Ph.D. (WHU Koblenz)
MBA/BBA (University of Saarbrücken)

Dr. Miguel Angel Ariño

Professor of Decision Sciences
IESE Business School
Barcelona, Spain (Universidad de Navarra)
CEIBS (China Europe International Business School).
Beijing, Shanghai and Shenzhen
Ph.D. in Mathematics
University of Barcelona
BA in Mathematics (Licenciatura)
University of Barcelona

Philip G. Moscoso

Technology and Operations Management
IESE Business School, University of Navarra
Ph.D in Industrial Engineering and Management, ETH Zurich
M.Sc. in Chemical Engineering, ETH Zurich

Dr. Sanjay Dixit, M.D.

Director, EP Laboratories, Philadelphia VA
Medical Center
Cardiovascular Medicine - Cardiac
Arrhythmia
Univ of Penn School of Medicine

Dr. Han-Xiang Deng

MD., Ph.D
Associate Professor and Research
Department Division of Neuromuscular
Medicine
Davee Department of Neurology and Clinical
Neuroscience
Northwestern University
Feinberg School of Medicine

Dr. Pina C. Sanelli

Associate Professor of Public Health
Weill Cornell Medical College
Associate Attending Radiologist
NewYork-Presbyterian Hospital
MRI, MRA, CT, and CTA
Neuroradiology and Diagnostic
Radiology
M.D., State University of New York at
Buffalo, School of Medicine and
Biomedical Sciences

Dr. Roberto Sanchez

Associate Professor
Department of Structural and Chemical
Biology
Mount Sinai School of Medicine
Ph.D., The Rockefeller University

Dr. Wen-Yih Sun

Professor of Earth and Atmospheric
SciencesPurdue University Director
National Center for Typhoon and
Flooding Research, Taiwan
University Chair Professor
Department of Atmospheric Sciences,
National Central University, Chung-Li,
TaiwanUniversity Chair Professor
Institute of Environmental Engineering,
National Chiao Tung University, Hsin-
chu, Taiwan.Ph.D., MS The University of
Chicago, Geophysical Sciences
BS National Taiwan University,
Atmospheric Sciences
Associate Professor of Radiology

Dr. Michael R. Rudnick

M.D., FACP
Associate Professor of Medicine
Chief, Renal Electrolyte and
Hypertension Division (PMC)
Penn Medicine, University of
Pennsylvania
Presbyterian Medical Center,
Philadelphia
Nephrology and Internal Medicine
Certified by the American Board of
Internal Medicine

Dr. Bassey Benjamin Esu

B.Sc. Marketing; MBA Marketing; Ph.D
Marketing
Lecturer, Department of Marketing,
University of Calabar
Tourism Consultant, Cross River State
Tourism Development Department
Co-ordinator , Sustainable Tourism
Initiative, Calabar, Nigeria

Dr. Aziz M. Barbar, Ph.D.

IEEE Senior Member
Chairperson, Department of Computer
Science
AUST - American University of Science &
Technology
Alfred Naccash Avenue – Ashrafieh

PRESIDENT EDITOR (HON.)

Dr. George Perry, (Neuroscientist)

Dean and Professor, College of Sciences

Denham Harman Research Award (American Aging Association)

ISI Highly Cited Researcher, Iberoamerican Molecular Biology Organization

AAAS Fellow, Correspondent Member of Spanish Royal Academy of Sciences

University of Texas at San Antonio

Postdoctoral Fellow (Department of Cell Biology)

Baylor College of Medicine

Houston, Texas, United States

CHIEF AUTHOR (HON.)

Dr. R.K. Dixit

M.Sc., Ph.D., FICCT

Chief Author, India

Email: authorind@computerresearch.org

DEAN & EDITOR-IN-CHIEF (HON.)

Vivek Dubey(HON.)

MS (Industrial Engineering),

MS (Mechanical Engineering)

University of Wisconsin, FICCT

Editor-in-Chief, USA

editorusa@computerresearch.org

Sangita Dixit

M.Sc., FICCT

Dean & Chancellor (Asia Pacific)

deanind@computerresearch.org

Suyash Dixit

(B.E., Computer Science Engineering), FICCTT

President, Web Administration and

Development , CEO at IOSRD

COO at GAOR & OSS

Er. Suyog Dixit

(M. Tech), BE (HONS. in CSE), FICCT

SAP Certified Consultant

CEO at IOSRD, GAOR & OSS

Technical Dean, Global Journals Inc. (US)

Website: www.suyogdixit.com

Email: suyog@suyogdixit.com

Pritesh Rajvaidya

(MS) Computer Science Department

California State University

BE (Computer Science), FICCT

Technical Dean, USA

Email: pritesh@computerresearch.org

Luis Galárraga

J!Research Project Leader

Saarbrücken, Germany

CONTENTS OF THE ISSUE

- i. Copyright Notice
- ii. Editorial Board Members
- iii. Chief Author and Dean
- iv. Contents of the Issue
 1. Comparative Study of Techniques in the Diagnosis of Mycoplasma Pneumonia among the Patients of Respiratory Tract Infections in Northern Indian Population. *1-4*
 2. Geographical Distribution of Factor V Laden in Different Regions of India. *5-8*
 3. Assessment of Clinician's Knowledge and Perception on Antimicrobial Resistance a Primary Strategy for Antimicrobial Resistance Control. *9-14*
 4. Prevalence of Resistant Strains of *Streptococcus Pneumoniae* to Oxacillin, Ofloxacin and Rifampicin in Abraka South-South Nigeria. *15-20*
- v. Fellows
- vi. Auxiliary Memberships
- vii. Process of Submission of Research Paper
- viii. Preferred Author Guidelines
- ix. Index



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 15 Issue 4 Version 1.0 Year 2015
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Comparative Study of Techniques in the Diagnosis of Mycoplasma Pneumonia among the Patients of Respiratory Tract Infections in Northern Indian Population

By Dr. Abhineet Mehrotra, Dr. S. K. Mehra, Dr. M E Siddque & Dr. Sushil Suri
Geetanjali Medical College, Udaipur

Abstract- Background: In the present study an attempt was made to compare the different diagnosis of mycoplasma pneumonia among the patients of respiratory tract infections in northern Indian population. Commonly used techniques in the diagnosis of mycoplasma pneumonia are culture, serology and PCR and different studies assure the different sensitivity and specificity. In the present study author also aim to find the common risk factors of mycoplasma pneumonia.

Material & Methods: The present study was undertaken at Career Institute of Medical Science, Lucknow. The total number of study subjects were 193. The total number of male subjects were 115 (59.6 %) while 78 (40.4 %) were females. Samples were Collected for culture, serology and PCR. All samples of culture & serology were undergone for PCR.

Results: Out of 193 patients 58 (30 %) samples were found positive in culture and 73 (38 %) samples were found to be positive in serology test. 58 patients were found to be positive by both culture and serology which are further tested in PCR and only 10 (17 %) samples were found positive.

Keywords: *mycoplasma pneumonia, culture, serology, PCR & risk factor.*

GJMR-C Classification : NLMC Code: WC 246, WC 202



Strictly as per the compliance and regulations of:



© 2015. Dr. Abhineet Mehrotra, Dr. S. K. Mehra, Dr. M E Siddque & Dr. Sushil Suri. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comparative Study of Techniques in the Diagnosis of Mycoplasma Pneumonia among the Patients of Respiratory Tract Infections in Northern Indian Population

Dr. Abhineet Mehrotra ^α, Dr. S. K. Mehra ^σ, Dr. M E Siddque ^ρ & Dr. Sushil Suri ^ω

Abstract- Background: In the present study an attempt was made to compare the different diagnosis of mycoplasma pneumonia among the patients of respiratory tract infections in northern Indian population. Commonly used techniques in the diagnosis of mycoplasma pneumonia are culture, serology and PCR and different studies assure the different sensitivity and specificity. In the present study author also aim to find the common risk factors of mycoplasma pneumonia.

Material & Methods: The present study was undertaken at Career Institute of Medical Science, Lucknow. The total number of study subjects were 193. The total number of male subjects were 115 (59.6 %) while 78 (40.4 %) were females. Samples were Collected for culture, serology and PCR. All samples of culture & serology were undergone for PCR.

Results: Out of 193 patients 58 (30 %) samples were found positive in culture and 73 (38 %) samples were found to be positive in serology test. 58 patients were found to be positive by both culture and serology which are further tested in PCR and only 10 (17 %) samples were found positive. The chi square test shows that respiratory & renal diseases may be considered as significant risk factors of Mycoplasma pneumonia ($p < 0.05$).

Keywords: mycoplasma pneumonia, culture, serology, PCR & risk factor.

I. INTRODUCTION

Mycoplasmas (mushroom form) are eubacteria included within the class Mollicutes (from latin mollis = "soft," cutis = "skin"), which comprises the smallest and simplest self-replicating, pleotrophic bacteria that lack cells wall thus, beta-lactam antibiotics, such as penicillin and cephalosporins, are ineffective. The name Mycoplasma, from the Greek μυκήs, mykes (fungus) and πλάσμα, plasma (formed), was first used by Albert Bernhard Frank in 1889¹. Mycoplasmas are primarily mucosal pathogens, living a parasitic existence in close

association with epithelial cells of their host, usually in the respiratory or urogenital tracts. M. pneumoniae exclusively parasitizes humans, whereas some of the other human mycoplasmas have also been recovered from nonhuman primates². Mycoplasma pneumoniae is an important cause of respiratory tract infection and is increasingly being associated with other diseases such as asthma and extra-pulmonary complications. Considerable cross-reactivity is known to exist between the whole cell antigens used in the commercial serological testing assays. Usually, mycoplasma infection is a mild illness characterized by fever, cough, bronchitis, sore throat, and headache. In very rare cases, mycoplasma can cause serious illness such as encephalitis (an inflammation of the brain) or meningitis (inflammation of the lining of the brain and spinal cord).

As the diagnosis the clinical symptomatology of a mycoplasma infection does not show pathogen-specific characteristics, the diagnostic differentiation from other pathogens such as viruses and gram-positive bacteria is decisive for appropriate therapy³. The diagnosis can be based on direct detection and serology. Detection of the pathogen has been regarded as efficient diagnosis at acute, early stages of disease. Isolation of the pathogen by culture has been considered the reference method. However, it is too insensitive and time-consuming (6-14 days). A good quality pathogen DNA detection system (PCR) is not yet commercially available. To date, serology has been considered the method of choice for diagnosis of infections. The complement fixation test (CFT) represents the classic antibody detection. The CFT cannot discriminate between antibody isotypes. Agglutination tests cannot discriminate between antibody classes either. Both test systems detect mainly the IgM antibody response. In reinfections both CFT and agglutination tests provide predominantly negative results. Nevertheless these test systems currently dominate the ELISA technology⁴. By using ELISA, IgG, IgA, and IgM, antibodies can be differentiated. The crucial factor for a specific and sensitive ELISA is the antigen.⁵

Author α: Research Scholar, Department of Microbiology, Geetanjali Medical College, Udaipur. e-mail: abhineetmehrotra@gmail.com

Author σ: Prof. & HoD, Department of Microbiology, Geetanjali Medical College, Udaipur.

Author ρ: Prof. & HoD, Department of Microbiology Career Institute of Medical Sciences & Research, Lucknow.

Author ω: Associate Professor, Department of Medicine, Career Institute of Medical Sciences & Research, Lucknow.

In the present study we try to evaluate the effective method in the diagnosis of mycoplasma pneumonia among three techniques i.e. Serology, Culture & PCR and an attempt was made to explore the socio demographic and clinical characteristics.

II. MATERIAL & METHODS

The present study was undertaken at Career Institute of Medical Science, Lucknow. The total number of study subjects were 286. The total number of male subjects were 115 (59.6 %) while 78 (40.4 %) were females. The present study protocol was approved by institutional ethical committee.

a) Culture, Serology and PCR

The expectorated sputum (throat swabs) and blood was collected from all patients. The *M. pneumoniae* standard strain was revived according to ATCC (American Type Culture Collection) 15531™ guidelines (www.atcc.org) which is commercially available in market. In brief, the lyophilized culture was resuspended in 6 ml pleuropneumonia like organism (PPLO) broth. A single drop was used to inoculate PPLO agar; 3 ml suspension was used to prepare glycerol stocks and stored at -70°C. The remaining 3ml suspension was incubated at 37°C and 5 per cent CO2 incubator till growth was observed with change in color from red to yellow. *Mycoplasma pneumoniae* strains are very slow growing and produce a very light turbidity. Growth in broth is best observed after 10 to 14 days of incubation. Usually it takes at least seven days for the first tubes to start showing growth. Growth is easily recognized by an indicator change from red to orange to yellow. The cells are best transferred when the medium is orange. After medium changes to yellow, cells have started to die. All the patients whose culture was found to be positive were taken for further consideration. The patients having positive culture were marked and further followed for serology. Only serum part which was separated from whole blood of those whose culture was positive. Serum was stored at -20°C till assayed. ELISA (Enzyme-Linked Immunosorbent Assay) kit is used for the accurate qualitative measurement of IgM class antibodies against *Mycoplasma pneumoniae* in Human serum and plasma. The clinical measurements were recorded. After serological test those patients were again used for follow up (for the purpose of PCR) whose culture as well as serology was found to be positive.as well as all other samples of culture and serology negative were also processed for PCR.

The sputum samples were collected in PBS were centrifuged at 1957 x g for 10 min. Supernatant was decanted and the pellet was resuspended in 0.5 ml PBS and stored at -70oC till further processing. The positive control consisted of relevant purified mycoplasma DNA. The extraction of DNA was done

using the organic methods described by Das et al [5]. A 543 bp section of the P1 protein gene of *M.pneumoniae* was selected for amplification. The primers (Bangalore Genei Pvt. Ltd., Bangalore, India) were:

Primer1: 5'CAAGCCAAACACGAGCTCCGGCC-3', which is complimentary to the P1 gene negative strand residues 3666-3688, and

Primer 2 : 5'CCAGTGTGTCAGCTGTTTGTCTTCCCC- 3', which is complimentary to the P1 gene positive strand residues 4208-4183.

Amplification was done according to the guidelines of Taq DNA polymerase (Bangalore Genei Pvt. Ltd., Bangalore, India). Amplified PCR products were subjected to electrophoresis on 3 ethidium bromide stained agarose gel, along with a molecular weight marker. A mixture of 2 µl genomic DNA, 2 µl of 6 X BPB and 8 µl of distilled water was loaded into the 1 per cent agarose gel. The electrophoresis was carried out at a constant voltage of 50 V for 1 h, and a band at 543 bp was taken to be a positive result. The PCR of those patients whose culture and serology was positive was carried out.

III. RESULTS

Table 1 represents the age wise distribution of study subjects. The total number of study subjects was 286. The total number of male subjects were 207 (72.4 %) while 79 (27.6 %) were females. Highest number of subject's i.e. 32.9 % subjects were less than 30 years while second highest number i.e. 30.4 % of study subjects was more than 45 years. Table 2 Gender wise distribution of study subjects. Table 3 shows the test result by different diagnosis technique of mycoplasma pneumonia. Out of 286 patients 168 (58.7 %) samples were found positive in culture and 98 (34.3%) samples were found to be positive in serology test. PCR testing shows only 80 (28 %) samples were found to be positive.

Table 1: Age and sex distribution of the study population (n = 286)

Age Group (years)	Sample	N (%)
<3	15	5.2%
3-5	21	7.3%
6-10	33	11.5%
11-15	19	6.6 %
16-30	94	32.9 %
31-45	87	30.4%
46-60	9	3.1%
>60	8	28 %




Figure 1

Table 2 : Gender wise distribution

Gender	N	%
Male	207	72.4
Female	79	27.6




Figure 2

Table 3 : Test results of sample

Test Result	Culture (n=286)	Serology (n=286)	PCR (n=286)
Positive Result	168(58.7%)	98 (34.3%)	80(28%)
Negative result	118(41.3%)	188 (65.7%)	206(72%)




Figure 3

a) Study design

This prospective cross-sectional study design will be used for the present study was conducted on community-acquired pneumonia in the Department of

Microbiology, at Career Institute of Medical Science, Lucknow.

b) Sample size calculation

Sample size was calculated by the sample size calculation formula for sing proportion by $n=4pq/d^2$, Where n: sample size, p: prevalence q: 1-p and d is specified absolute precision by assuming prevalence 21 %, with specified absolute precision 0.06 and 10 % data loss, be. Calculated sample size is 260. Adding 10% non-response, the final sample size is 286.

Sample size is 260. Adding 10% non-response, the final sample size is 286.

i. Inclusion criteria

Patients clinically diagnosed clinical and radiological proven of atypical pneumonia will be included in the study with,

1. Community acquired pneumonia (CAP):
2. Presence of a new pulmonary infiltrate/ shadow on chest X-ray suggestive of pneumonia at/ within 24 h of hospitalization.
3. Patient residing in community.

ii. Exclusion criteria

1. Hospital acquired pneumonia i.e. pneumonia that developed 72 h after hospitalization or within 7 days of discharge.
2. Pulmonary shadow due to a cause other than pneumonia.
3. The serious patients having other disease with atypical pneumonia will be excluded

A written informed consent was taken from the parent/legal guardian of the children before them being enrolled in the study.

Clinical data from the patients were collected using a questionnaire developed and validated and a detailed examination was performed. Routine laboratory investigations were done in all subjects. In the present study culture, serology and PCR technique is used to diagnose the mycoplasma pneumonia.

IV. DISCUSSION

A variety of techniques are used to assess *M. pneumoniae*, each with different advantages and disadvantages. In this study, PCR, ELISA, and culture methods were employed for the detection of *M. pneumoniae* infection in 286 suspected patients. The culture method for the isolation of *M. pneumoniae* requires 2–4 weeks, which limits itsclinical usefulness. Moreover, culturing of *M. pneumoniae* is expensive and time-consuming (7-10). Serological methods are more extensively used than culture, because they are easier to carry out and more affordable (11-13).However, they are generally nonspecific, retrospective, and need 2 samples for titration⁷. It should be noted that in our study, the most reliable result was obtained by the PCR method, which proved to be highly sensitive, specific,

and faster than other methods. The specificity of the culture method was 100%, while its sensitivity barely reached 33%, relative to the results of the PCR method as a gold standard. All of the culture and IgM ELISA test positive patients were PCR-positive, too. The PCR method is more sensitive and is the gold standard currently being used for diagnosis of this organism in some laboratories¹⁴

V. CONCLUSION

In the present study it is concluded that only one technique may not be sufficient to diagnose the mycoplasma pneumonia as these techniques do not show higher sensitivity and specificity as many results suggest the same [6]. However, serology and culture is done commonly.

VI. ACKNOWLEDGMENT

The authors acknowledge the help provided by various faculties, technicians and paramedical staffs of Career Institute of Medical Sciences, Lucknow, for providing patient samples. Authors would like to acknowledge the Dean/Director of the institute to provide great support.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Shin DH, Kim J-S, Yokota H, Kim R, kim S-H. Crystal structure of the DUF16 domain of MPN010 from *Mycoplasma pneumoniae*. *Protein Science: A Publication of the Protein Society*. 2006; 15 (4): 921-928. doi:10.1110/ps.051993506.
2. Ken B. Waites and Deborah F. Talkington Clin. Microbiol. Rev. October 2004 vol. 17 no. 4 697-7281 October 200 doi: 10.1128/CMR.17.4.697-728.2004
3. http://www.medac.de/medac_international/data/diagnostics Specific and sensitive diagnosis Mycoplasma pneumoniae IgG-, IgA-, IgM-ELISA(nb)
4. Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL. Analysis of Eight Commercial Enzyme Immunoassay Tests for Detection of Antibodies to *Mycoplasma pneumoniae* in Human Serum. *Clinical and Diagnostic Laboratory Immunology*. 2004; 11 (5): 862-867. doi: 10.1128/CDLI.11.5.862-867.2004.
5. Bineeta Kashyap, Surinder Kumar, G.R. Sethi*, B.C.Das** & S.R. Saigal Comparison of PCR, culture & serological tests for the diagnosis of Mycoplasma pneumoniae in community-acquired lower respiratory tract infections in children Indian J Med Res 128, August 2008, pp 134-139
6. Zhang L, Zong Z-Y, Liu Y-B, Ye H, Lv X-J. PCR versus serology for diagnosing *Mycoplasma pneumoniae* infection: A systematic review & meta-analysis. *The Indian Journal of Medical Research*. 2011; 134 (3): 270-280.
7. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of *Mycoplasma pneumoniae* infections. *FEMS Microbiol Rev* 2008; 32: 956-73.
8. Ma LD, Chen M, Dong Y, Fan J, Xia L, Wang S et al. Rapid *Mycoplasma* culture for the early diagnosis of *Mycoplasma pneumoniae* infection. *J Clin Lab Anal* 2010; 24: 224-9.
9. Sasaki T, Kenri T, Okazaki N, Iseki M, Yamashita R, Shintani M et al. Epidemiological study of *Mycoplasma pneumoniae* infections in Japan based on PCR-restriction fragment length polymorphism of the P1 cytoadhesin gene. *J Clin Microbiol* 1996; 34: 447-9.
10. Waites KB, Talkington DF. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev* 2004; 17: 697-728.
11. Liu FC, Chen PY, Huang FL, Tasai CR, Lwee CY, Wang LC. Rapid diagnosis of *Mycoplasma pneumoniae* infection in children by polymerase chain reaction. *J Microbiol Immunol Infect* 2007; 40: 507-12.
12. Dunn JJ, Malan AK, Evans J, Litwin CM. Rapid detection of *Mycoplasma pneumoniae* IgM antibodies in pediatric patients using ImmunoCard Mycoplasma compared to conventional enzyme immunoassays. *Eur J Clin Microbiol Infect Dis* 2004; 23: 412-4.
13. Daxboeck F, Krause R, Wenissch C. Laboratory diagnosis of *Mycoplasma pneumoniae* infection. *Clin Microbiol Infect* 2003; 9: 263-73.
14. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H. Evaluation of 12 commercial tests and the complement fixation test for *Mycoplasma pneumoniae*-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". *J Clin Microbiol* 2005; 43: 2277-85.



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 15 Issue 4 Version 1.0 Year 2015
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Geographical Distribution of Factor V Laden in Different Regions of India

By Dr. Pushpalatha Manjunatha, Dr. Satish Kumar Amarnath, Arun Kumar H. R,
Bala Satish M & S. J. Sabarish Babu

Ecron Acunova, India

Abstract- Background: Factor V Leiden is the most common inherited form of thrombophilia with 3 to 8 percent European and American ancestry carrying one copy of the factor V Leiden mutation in each cell, and about 1 in 5,000 people have two copies of the mutation. The mutation is less common in Asian, Hispanic and African populations.

Aim: This study was carried out to know the incidence of Factor V mutation in various regions of India.

Methods: The presence of factor V mutation was determined by PCR- RFLP from patients suspected of thromboembolic etiology from medical, surgical, obstetrics and neonatology departments.

Results: Analysis of 94 patients with coagulation disorders, factor V mutation was seen in 20 cases.

Discussion: Although many reports from India indicate the absence of this mutation or the presence of homozygous mutation in a low level we report about 26 percent of the cases having the homozygous mutation which is the first for India.

GJMR-C Classification : NLMC Code: QW 4



Strictly as per the compliance and regulations of:



© 2015. Dr. Pushpalatha Manjunatha, Dr. Satish Kumar Amarnath, Arun Kumar H. R, Bala Satish M & S. J. Sabarish Babu. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Geographical Distribution of Factor V Laden in Different Regions of India

Dr. Pushpalatha Manjunatha ^α, Dr. Satish Kumar Amarnath ^σ, Arun Kumar H. R ^ρ, Bala Satish M ^ω
& S. J. Sabarish Babu [¥]

Abstract- Background: Factor V Leiden is the most common inherited form of thrombophilia with 3 to 8 percent European and American ancestry carrying one copy of the factor V Leiden mutation in each cell, and about 1 in 5,000 people have two copies of the mutation. The mutation is less common in Asian, Hispanic and African populations.

Aim: This study was carried out to know the incidence of Factor V mutation in various regions of India.

Methods: The presence of factor V mutation was determined by PCR- RFLP from patients suspected of thromboembolic etiology from medical, surgical, obstetrics and neonatology departments.

Results: Analysis of 94 patients with coagulation disorders, factor V mutation was seen in 20 cases.

Discussion: Although many reports from India indicate the absence of this mutation or the presence of homozygous mutation in a low level we report about 26 percent of the cases having the homozygous mutation which is the first for India.

I. INTRODUCTION

Factor Van Leiden mutation has been reported in 3 to 8 percent of the Caucasian population with thrombophilia, and absolutely absent in Hispanics, African and Asian populations in the US.

Factor V Leiden named after the city Leiden (The Netherlands), was first identified in 1994 by Prof R. Bertina et al. In normal individuals Activated protein C (APC) prevents blood clots from growing too large by inactivating factor V. In factor V Leiden mutation, there is single nucleotide substitution of adenine for guanine (single nucleotide polymorphism) changes the protein's 506th amino acid from arginine to glutamine, which is the cleavage site for APC (Bertina et al).

Factor V Leiden can be associated with the following complications such as deep vein thrombosis (DVT), superficial thrombophlebitis, sinus vein thrombosis, mesenteric vein thrombosis, Budd-Chiari syndrome, pulmonary embolism (PE), recurrent unexplained miscarriage, preeclampsia and/or eclampsia.

PCR is a simple genetic test that can be done for diagnosis of factor V mutation. The mutation

(1691G→A substitution) removes a cleavage site of the restriction endonuclease MnlI, which can be detected by PCR - RFLP.

In Asian-Indian populations 1% to 8.5% has been reported. In Tamil Nadu, south India, 4 out of 72 were reported to be heterozygous for FVL mutation (5.5%), while none were detected for homozygous mutation. Another study to know the association between portal vein thrombosis and FVL, reported 4.1% heterozygous mutation for factor in healthy Indians. However, contradictory results were found when the presence of this mutation was studied in healthy populations from Turkey, Korea, and even from some Indian populations (Wan Zaidah Abdullah et al 2009).

The presence of the mutation markedly increases the risk for renal vein thrombosis, particularly in neonates, and renal transplant vein thrombosis in transplant cases resulting in rejection. Routine screening for factor V Leiden mutation by polymerase chain reaction, and appropriate perioperative and postoperative anticoagulation after renal transplantation might be a valuable strategy to prevent thromboembolic complications in transplant recipients (Craig J Della Valle MD et al).

The factor V Leiden mutation is associated are two to three times more likely to have recurrent miscarriages or a pregnancy loss during the second or third trimester (8).


II. MATERIALS AND METHODS

A total of 94 samples were received from patients attending medicine, surgery, neonatology and OBG departments from April 2007 to December 2010 from different states like Karnataka (2, 24.5%), Andhra Pradesh (43, 45.7%), Punjab (18, 19%) West Bengal (5, 5.9%) and Nepal (2, 2.1%). Patients with history of spontaneous DVT, postsurgical, venous thrombosis, haemorrhagic infarct, stroke, unexplained DVT, primary DVT, hypercoagulable state. The EDTA blood samples were shipped at - 20°C, DNA extraction was done using Qiagen DNA columns. The samples were analyzed for mutant gene by Polymerase Chain Reaction - Restriction Fragment Length Polymorphism (PCR - RFLP) followed by analysis of fragments of digestion by gel electrophoresis. Positive and negative controls were included in the assay, normal (wild) sample showed 3 bands at 86, 46 and 37 bp region, and positive control

Author α ρ ω ¥: Central Laboratory, Manipal Acunova Ltd, Mobius Towers, SJR i - Park EPIP, Whitefield, Bangalore.
e-mail: pushpa.teju.m@gmail.com

Author σ: Head Quality, compliance and Outreach Services, Manipal Cure and Care, Manipal Towers, 14, HAL Airport Road, Bangalore.
e-mail: Satish.amarnath@gmail.com

showed 2 bands at 123 and 46 bp region, and negative control did not show any bands. The procedure was followed as per Craig J Della Valle MD et al. 2001.



III. RESULTS

Out of 94 samples screened for the mutation, in the age group ranging from zero to 65 years of age. Of the total 59 were males, age ranging from 1 day to 60 years, with a mean age of 33.5 and a stdev of 16.2. Among the 35 females studied, the age range was 1 day to 60 with a mean of 34.7 and stdev of 12.4. Of these 46 (48.9%) were from Andhra Pradesh, 23(24.5%) from Karnataka from southern region, 19.1% from Punjab in the north, 5.3% from west, and 2.1% from Nepal.

20 samples were positive for heterozygous mutation, 11 were males in the age group in the range of 1 year to 60 years with a mean of 33 and stdev of 16. In the female cases 9 were positive in the age group in the range of 20 years to 40 years with a mean of 29.8 and stdev of 6.6.

A total of 20 patients were positive for heterozygous mutation, of which 11 were males and 9 were females. 7 cases (7.4%) were from Punjab, of which 5 were females and 2 were males constituting 35% of the positives. These cases were obtained by screening 18 suspected cases from Punjab, giving a positive rate of 35%. Even though 43 cases were screened from Andhra Pradesh, 9 were positive of which 5 were males and 4 were females accounting to 18%, with positive rate of 45%, 3 from Karnataka all 3 were males with a positive rate of 15%, 1 male from West Bengal with a positive rate of 5%. All the positive samples showed two bands for heterozygous mutation of Factor V Leiden, while the wild type showed 3 bands.

IV. DISCUSSION

The present study was carried out in patients with various clinical conditions such as, spontaneous DVT, post-surgical venous thrombosis, hemorrhagic infarct, stroke, unexplained DVT, primary DVT, hypercoagulable state and pregnant women with history

of miscarriages. 20 out of 94 patients had FVL, our findings were similar to the largest series reported from Singapore.

As per Gupta et al both these polymorphisms were totally absent in Indian population, and cannot be considered as independent risk factors or as a predictor for CAD (Gupta N et al. 2003). Factor V Leiden and G20210 prothrombin gene mutations are infrequent in Indian patients with PVT and are unlikely to be responsible for PVT in the Indian population (Sharma S et al. 2006).

There were no association of FVL mutation and prothrombin gene mutation in genetic predisposition to CADs and MI in north Indian population. The discrepancies in studies relating to FVL mutation and FII G20210A allele to CADs may be due to difficulties in estimating low allelic frequency in general population (Gupta N et al. 2003).

The prevalence have been estimated for Poland (Warsaw) 5.0%, Argentina (Buenos Aires) 5.1%, Venezuela (Valencia) 1.6%, Costa Rica (San José) 2.0%, and India (Punjab) 1.3%. Based on worldwide distribution, it can be hypothesized that the factor V Leiden mutation has originated and accumulated in central European Caucasians and spread over the world by migration (Herrmann FH et al 1997). The allele frequency in 618 Europeans was 4.4%, with the highest prevalence among Greeks (7%) and 0.6% in Asia Minor. Factor V Leiden was not found in any of 1600 chromosomes from Africa, Southeast Asia, Australasia, and the Americas, which explains the rarity of thromboembolic disease in these populations (Rees DC et al 1995).

FVL mutations, usually rare in populations other than Caucasians, exceptions do exist. In Asian-Indian populations 1% to 8.5% has been reported. In Tamil Nadu, south India, 4 out of the 72 were reported to be heterozygous for FVL mutation (5.5%). Another study

was aimed at finding a possible association between portal vein thrombosis and FVL, and it reported a slightly lower prevalence in its control group of healthy Indians (4.1% were heterozygous for this mutation). However, contradictory results were found when the presence of this mutation was studied in healthy populations from Turkey, Korea, and even from some Indian populations). Singapore report says 10.74% (6.84, 14.64) of Indian patients were positive for FVL mutation, while less than 0.5% and 1.83% were detected as positive among Chinese and Malay patients respectively (Wan Zaidah Abdullah et al 2009). The factor V Leiden mutation is associated are two to three times more likely to have recurrent miscarriages or a pregnancy loss during the second or third trimester (genetic home reference).

VTE consists of 2 related conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). Between 20% and 60% of patients with recurrent VTE display APC resistance on laboratory testing, which is mostly due to mutation in the factor V gene. Among the European white population, the factor V Leiden mutation is the most prevalent hereditary thrombophilia. Approximately 4% to 6% of the general population are heterozygous for this trait (which is autosomal dominant), but it is extremely rare among native populations of Africa, Southeast Asia, and Australia (Frederick A et al).

The presence of the mutation markedly increases the risk for renal vein thrombosis, particularly in neonates, and renal transplant vein thrombosis in transplant cases resulting in rejection. Routine screening for factor V Leiden mutation by polymerase chain reaction, and appropriate perioperative and postoperative anticoagulation after renal transplantation might be a valuable strategy to prevent thromboembolic complications in transplant recipients (R P Wüthrich et al).

The prevalence of FVL in the general population varies from 0% to 7%, which is common in Europe and being almost absent in Africa and the Middle East. In patients with venous thrombosis, the prevalence is higher at 19% in the Netherlands and 39% in northern India but is only 3% in Mumbai. In patients with PVT, the prevalence is 7.6% in the Netherlands and 8% in Mumbai. The highest prevalence of 30% has been reported in a study of Egyptian children with PVT (Abraham Koshy et al).

In our study, 20 patients were positive for heterozygous mutation, of which 11 were males and 9 were females who had clinical history of thromboembolic disorders. Particularly 9 females in the reproductive age group most probably with a history of eclampsia. One male baby one day old was positive from AP.

Patients with recurrent thrombotic events related to factor V Leiden mutation have been reported, e.g. deep venous thrombosis in the lower limb followed by

cerebral venous thrombosis resulting in quadriplegia. Awareness of the condition and a high index of suspicion is needed to prevent life-threatening complications. It is important to screen all patients less than 50 years of age presenting with spontaneous lower limb deep venous thrombosis are screened for factor V Leiden mutation (Meenakshi et al).

Molecular and epidemiological studies provide evidences that FVL should have occurred as a single event in the past. The Mediterranean region has the highest prevalence of FVL in the world, suggesting the origin of mutation possibly 10,000 years ago, and later spread to other parts of the world (Herrmann FH et al).

Venous thrombosis is a common problem, predominantly affecting people of European origin. This European predisposition has been explained to some extent by the recent characterization of factor V Leiden, and the G20210A prothrombin variant. Analysis of 22 samples for FVL from different non-European countries showed that prothrombin variant is very rare outside Europe except for one case from India (Rees DC et al).

REFERENCES RÉFÉRENCES REFERENCIAS

1. Craig J Della Valle MD, Paul S Isaac, Avi Baitner, David J Steiger, Carrie Fang and Paul E Di Cesare. The relationship of the factor V Leiden mutation and the deletion- deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. *BMC Musculoskeletal Disorders* (2001) 2:1.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 1994;369:64-7.
3. Gupta N, Khan F, Tripathi M, Singh VP, Tewari S, Ramesh V, Sinha N, Agrawal S. Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. *ORIGINAL ARTICLE* 2003;57 (12):535-42.
4. Herrmann FH, Koesling M, Schröder W, Altman R, Jiménez Bonilla R, Lopaciuk S, Perez-Requejo JL, Singh JR. Institute of Human Genetics, University of Greifswald, Germany. Prevalence of factor V Leiden mutation in various populations *Genet Epidemiol.* 1997;14 (4):403-11.
5. Meenakshi-Sundaram, Rohini Sridhar, JJ Jithendrian, RN Durai, MJ Arunkumar, Bharathi Sundar. Case Report Recurrent Venous Thrombosis with Factor V Leiden Mutation. *JAPI.* 2005 July; 53:642-644.
6. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. *Lancet* 1995;346:1133-34.
7. Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J, Clegg JB. Born to clot: the European burden. *Br J Haematol.* 1999 May;105 (2):564-6.

8. <http://www.genome.gov/15015167#Q5>.
9. Wan Zaidah Abdullah, Subashini Kumaraguru, Selamah Ghazali, Narazah Mohd Yusoff. Factor V Leiden and Prothrombin G20210A Mutations Among Healthy Indians in Malaysia. LABMEDICINE ■ 2010 May;5 (2):284-287.
10. Abraham Koshy, Mary Jeyakumari. Factor V Leiden is not commonly associated with idiopathic portal vein thrombosis in southern India. Indian society of Gastroenterology 2006 May – June (25):140 -142.
11. Frederick A. Anderson, Jr. and Frederick A. Spencer Risk Factors for Venous Thromboembolism. JOURNAL OF AMERICAN ASSOCIATION. *Circulation* 2003, 107:I-9-I-16.
12. R P Wüthrich. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Biological Sciences › Genetics Papers 1. Hypertension (2001). Volume: 10, Issue: 3, Pages: 409-414.





GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 15 Issue 4 Version 1.0 Year 2015
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Assessment of Clinician's Knowledge and Perception on Antimicrobial Resistance a Primary Strategy for Antimicrobial Resistance Control

By Dr. N. Shanmuga vadivoo, Dr. B. Usha & Dr. B. K Padmavathi

Annapoorana Medical College, India

Abstract- Introduction & back ground: Antimicrobial resistance (AMR) develops with the inappropriate use, which includes the wrong indication, mode of use, and the poor adherence of the prescribed drugs. Knowledge is the first step in modifying behaviour in relation to physician's adherence to antibiotics prescription practice.

Methods: We did a cross sectional survey of 737 doctors at three tertiary care teaching hospital to assess their Knowledge, perception and attitude regarding Antimicrobial resistance. Anaesthetists, Pre & para clinical doctors who were general practitioners also participated in the survey.

Results: About 93% of doctors strongly agreed /agreed that AMR is a worldwide problem; only 75% rated that it's a problem in their institution. Nearly 85% doctors believed that inappropriate antibiotics use were important cause of Resistance. Also only 81% agreed that poor infection control measures & poor isolation precautions contribute to AMR. Another survey following a CME showed that educational intervention plays an important role in updating clinicians AMR knowledge.

Keywords: antimicrobial resistance, KAP survey, clinicians & para clinicians.

GJMR-C Classification : NLMC Code: QW 4



ASSESSMENT OF CLINICIAN'S KNOWLEDGE AND PERCEPTION ON ANTIMICROBIAL RESISTANCE A PRIMARY STRATEGY FOR ANTIMICROBIAL RESISTANCE CONTROL

Strictly as per the compliance and regulations of:



© 2015. Dr. N. Shanmuga vadivoo, Dr. B. Usha & Dr. B. K Padmavathi. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Assessment of Clinician's Knowledge and Perception on Antimicrobial Resistance a Primary Strategy for Antimicrobial Resistance Control

Dr. N. Shanmuga vadivoo ^α, Dr. B. Usha ^σ & Dr. B. K Padmavathi ^ρ

Abstract- Introduction & back ground: Antimicrobial resistance (AMR) develops with the inappropriate use, which includes the wrong indication, mode of use, and the poor adherence of the prescribed drugs. Knowledge is the first step in modifying behaviour in relation to physician's adherence to antibiotics prescription practice.

Methods: We did a cross sectional survey of 737 doctors at three tertiary care teaching hospital to assess their Knowledge, perception and attitude regarding Antimicrobial resistance. Anaesthetists, Pre & para clinical doctors who were general practitioners also participated in the survey.

Results: About 93% of doctors strongly agreed /agreed that AMR is a worldwide problem; only 75% rated that it's a problem in their institution. Nearly 85% doctors believed that inappropriate antibiotics use were important cause of Resistance. Also only 81% agreed that poor infection control measures & poor isolation precautions contribute to AMR. Another survey following a CME showed that educational intervention plays an important role in updating clinicians AMR knowledge.

Conclusion: Although most doctors view antibiotic resistance as a serious national problem, perceptions about its local importance, its causes and possible solutions vary widely. Overall, most of our clinicians had better understanding and surprisingly Pre & Para clinical doctors also have enough knowledge regarding Antibiotics practice.

Keywords: antimicrobial resistance, KAP survey, clinicians & para clinicians.

I. INTRODUCTION

Antimicrobial resistance (AMR) a global problem is particularly pressing in developing countries where the Health care associated infection (HCAI) burden is high and cost constrains the replacement of older antibiotics with newer, more expensive ones. Several studies ⁽¹⁻⁴⁾ have identified the inappropriate use of antimicrobials and noncompliance with infection control precautions as the main risk factors associated with an increased probability of colonization with resistant pathogens and there by Antimicrobial resistance. Hence management of common and lethal

bacterial infections has been critically compromised by the rapid appearance & spread of these antibiotic-resistant bacteria ⁽⁵⁾. The pipeline of antibiotic research and development is nearly dry, especially when it comes to antibiotics active against Gram-negative bacteria ⁽⁶⁾. The bacterial disease burden in India is among the highest in the world; consequently, antibiotics play a critical role in limiting morbidity and mortality in the country. This has led to increasing use of newer antibiotics and ultimately ended up with increased prevalence rates of Multi drug resistant bacteria. Though we all know that Abuse, overuse & Misuse of antibiotics have exacerbated Antibiotic resistance, resistance development is a natural unstoppable process. Hence our challenge is to slow the rate at which resistance develops & spreads. Combating Antimicrobial resistance calls for a concerted approach from individuals to global levels involving various organisations like CDC, WHO, Health ministry of India and other organisations ^[6, 7]. These organizations recommends all the health care facilities to have their own Antibiotic policy based on Local Cumulative antibiogram ⁽⁸⁾ and to implement antibiotic stewardship programme ⁽⁹⁾ accordingly to combat the most prevalent MDR pathogens at their own hospital settings.

II. BACKGROUND

Many strategies have been proposed for the rational use of antibiotics, like a formulary replacement or restriction, health care provider education, feedback activities, approval requirement from an infectious disease specialist for the drug prescription ^[9]. Various studies which were done in India and other developed countries have highlighted the importance of rational drug therapy through educational interventions, strict antibiotic policy and Stewardship ^(9, 10, 11).

Knowledge is the first step in modifying behaviour in relation to physician's adherence to clinical practice & Guidelines. Therefore a very important primary strategy for framing an Institutional Antibiotic policy is assessment of Clinicians' Knowledge and their perception about Antimicrobial resistance. Also assessment of antibiotics prescription practice &

Author α σ ρ: Associate professor, Department of Microbiology Annapoorana medical college & Hospital Periyaseeragapaadi, SALEM-636 308. e-mails: shanmugavadivoon@gmail.com, dr_ushasekar@yahoo.co.in, bk.padmavathi@yahoo.in

knowledge about the driving forces behind antibiotics prescription followed by educational intervention plays a very important role. The assessment is usually done by Knowledge, perception & attitude survey based on LIKERTs scale. Studies on clinicians' attitude towards Knowledge, perception of Antimicrobial resistance have been published in both Community and Hospital settings [12-22]. Some of these studies have shown poor correlation between knowledge and practice. Hence the purpose of this study is to conduct a survey to assess and explore Knowledge, attitude & Perception of clinicians' towards antimicrobial resistance at three tertiary care centre.

III. MATERIAL & METHODS

This study is a cross sectional survey from three tertiary care teaching hospitals during 2014. All the three are located in suburban areas with 530, 900 & 300 beds respectively. Clinicians of above mentioned three tertiary care centres belonging to following specialities like General medicine, Surgery, Obstetrics Gynaecology, Paediatrics, Orthopaedics and super specialities like Nephrology, Urology, Paediatric surgery and Resident doctors working in all the above mentioned speciality participated. Anaesthesia & Para clinical doctors who were general practitioners also participated in the survey.

The Study instrument: The survey was carried out with a structured, validated, anonymous questionnaire encompassing sessions to assess Knowledge & perception of Clinicians towards Antibiotic Resistance. The Questionnaire was reviewed by Institutional Ethical Committee team to assess the relevance & Wordings of questions. The willing participants were approached individually and were requested to fill in the questionnaire anonymously. The Questionnaire was distributed onsite during working hours. No incentives for subjects to participate and no reminders were given.

The response to questionnaire was assessed in FIVE point Likert scale ranging from strongly agrees to strongly disagree. Briefly the questionnaire consisted of

- Professional profile of area of speciality, staff position, experience in that speciality.
- Section-1-Question pertaining to knowledge about Antimicrobial resistance like awareness at Global, national level and community level.
- Section-II-Question pertaining to practices known to contribute to Antimicrobial Resistance.
- Section-III-Questions pertaining to factors involved in antibiotic prescribing practices.
- Section-IV-Questionnaires were Drivers of choice in decision making to prescribe antibiotics.

Following the Questionnaire survey and based on the feedback, a CME on Antimicrobial resistance, Basic infection control practices, Antibiotic policy and

Stewardship was organised. Again a Post CME survey in a questionnaire format to assess the Knowledge transfer was given to the Clinicians which consisted of Questionnaire on Necessity for Role of hand hygiene, Isolation precautions, Antibiotic policy & Stewardship programme for reducing Antimicrobial Resistance

IV. RESULTS

A total of 737 doctors filled in the questionnaire. An overview of the professional profile of the 737 participants are given in Figure-1. The staff position and years of experience in that particular field shown in Table-1. Table-2 gives the profile of different specialities of physicians & Surgeons from different centres. Anaesthetists and Para clinical doctors were also included in our study because many of them were practicing physicians.

Table 1 : Professional profile of the participants

Staff position	Number	%	Years of experience
Prof/Associate prof	170	23%	18-25 years
Assistant prof	125	17%	6-10 years
Senior and Junior Residents	361	49%	1-8 years
Consultants	81	11%	10-15 years

Table 2 : Department wise statistics of the participants

Speciality	Total	Percentage
Anaesthesia	30	4.1%
General medicine	103	14.1%
General surgery	94	12.5%
OBG	88	12%
Paediatrics	76	10.5%
Orthopaedics	63	8.5%
Ophthalmology	25	3.4%
ENT	21	2.8%
Dermatology	23	3.1%
Chest/TB	15	2%
ICU	81	11%
Surgical super speciality	10	1.4%
Medical Super speciality	15	2%
Pre/Para clinical	93	12.6%
TOTAL	737	100%




Figure 1 : Overall Demographic profile

Knowledge on Antimicrobial use and Antimicrobial resistance rates is shown in Figure-2. About 93% of doctors strongly agreed /agreed that AMR is a worldwide problem. Response to practices known to contribute AMR is shown in Table-3 .Antibiotic

prescription practices and drivers of choice for Antibiotics are shown in table 4 & Table-5 respectively. Data's on Post CME questionnaire survey is shown in TABLE-6.

Table 3 : Practices known to contribute to antimicrobial resistance

	Strongly Disagree	Disagree	Neither	Agree	Strongly Agree
Failure to properly diagnose patients infective conditions	2.5%	16%	9.2%	48.3%	24
Prescribing antimicrobials when they are not needed	4.1%	5.5%	8.4%	37	45
Limited use of laboratory services for infection diagnosis	2.5%	7.1%	8.4%	56%	26%
Poor Adherence to isolation and contact precautions	1%	8.4%	9.6%	58.4%	22.6%
Poor hand hygiene & Poor infection control	1.2%	10.5%	8%	40.3%	40
Patients demand for Antibiotics	3.5%	20.5%	22%	40%	14%
Patients failing to adhere to treatment	0	4.2%	3.3%	45%	47.5%

Table 4 : Antibiotic Prescribing Practices

	Strongly Disagree	Disagree	Neither	Agree	Strongly Agree
Microbiology lab results are efficiently communicated to the treating physician.	2.9%	8.4%	5.5%	41.1%	42.1%
I regularly refer to the susceptibility/sensitivity patterns at this institution (e.g., an antibiogram) when prescribing antibiotics	2.1%	6.3%	12.6%	53%	26%
If medically appropriate IV antibiotics should be stepped down to an oral alternative	3.3%	4.6%	5.6%	58.4%	28.1%
A majority of patients admitted to this institution will be prescribed at least one antibiotic during their hospital stay	1.2%	5.8%	21.8%	52.5%	18.7%
Many of my patients receive 5 or more days of antibiotics during their stay at this institution.	4.2%	9.6%	13.4%	51.2%	21.6%
Only Few of my patients are discharged from this institution on antibiotics.	2.5%	9.2%	19.5%	56.5%	12.5%

Table 5 : Opinion on the Drivers of Choice of Antibiotic for a Particular Infection?

	Strongly Disagree	Disagree	Neither	Agree	Strongly Agree
Severity of infection	1.2%	2.1%	2.9%	50.8%	43%
Likely infecting organisms	0	0.4%	3.7%	63%	32.9%
Lab results	0.7%	2.9%	8.4%	58.4%	29.6%
Effectiveness of antibiotics for patients typically seen	1.2%	3.3%	12.6%	62.1%	20.85
Recommendations' by the pharmacists	27.7%	48.3%	10.5%	3.5%	10%

Table 6 : Post CME Questionnaire Survey

	Strongly Disagree	Disagree	Neither	Agree	Strongly Agree
Essential Infection control practices like Hand Hygiene reduce Health care Associated Infections	0	0	0	37%	63%
Isolation Precautions will significantly reduce Health care Associated Infections	0	0	15%	43%	42%
Do you think Antibiotic policy will help to reduce Antimicrobial resistance in this Institution	0	7%	11%	58%	24%
Do you think Antimicrobial stewardship programs can improve patient care?	0	0	3%	81%	16%
According to you will Antimicrobial stewardship programs reduce the problem of antimicrobial resistance?	0	0	15%	69%	16%
In your opinion will you be able to benefit or update your knowledge by this CME organised by the institution pertaining to Infection Control Programme?	0	0	0	62%	38%




Figure 2 : Antibiotic Resistance -Awareness

V. DISCUSSION

One of the emerging public health problems is AMR and no effective first line drugs exist for resistant pathogens. Inappropriate Antibiotics use & Infection control noncompliance has been primary attributes for dramatic raise in antimicrobial resistance.

The present study describes the results of a KAP-survey among 737 medical doctors (From all the specialities) practicing in three tertiary care teaching hospitals .Our study was done to assess the knowledge, attitude and the perception among the practitioners at a hospital setting towards a rational use of antibiotics.

The awareness of AMR problem worldwide, national & Institutional level and in their practice by

clinicians at three centres varied .In our study significant percentage of clinicians (90%) perceived that Antibiotic resistance is a problem Worldwide& national level and less percentage (75%) in their institutional level as shown in Fig-2. In contrast to our study, a high perception that AMR as an institutional problem was shown in studies by Arjun Srinivasan ⁽¹⁸⁾ *etal*, and Maha et al ⁽²¹⁾.Our data is similar to a study by Wester *etal* ⁽²¹⁾ where in 87% respondents agreed that Antibiotic resistance is a national problem and 55% perceived it to be a problem in their institution. In a study by Giblin *etal* ⁽¹⁶⁾ 89% respondent's choice was national problem and 73% in their own institution and 65% in their practice. This disparity among clinician's perception demonstrates a lack of awareness & understanding

regarding the problem. Therefore, until the clinician's perception changes towards the fact that even in their personal practice their patients are also susceptible to AMR they will not have any motivation to change their practice behaviour particularly with respect to antibiotics use.

Regarding our clinician's response to practices contributing to AMR, 93% agreed that patient's failure to adhere to treatment an important contributor of AMR as shown in TABLE-3. In contrast, a study by Maha *etal*⁽¹⁶⁾ showed only 68% agreed that patient's failure to adhere to treatment an important contributor of AMR. Our study also showed only 80% of respondents agreed that poor adherence to infection control practices like isolation precaution & Hand hygiene contributes to antibiotic resistance. In a study by Shah *etal*⁽²⁰⁾ only 31% respondents agreed that hand hygiene is significant in reducing antibiotic resistance. 54% of respondents agreed that patients demand for antibiotics a contributing factor to Antibiotic resistance. A similar data was shown by Sivagnanam⁽¹²⁾ *etal* and Garcia *et al*⁽¹⁴⁾ where in 55% of respondents agreed patients demands for antibiotics a contributing factor .

Among the data's on clinicians antibiotics prescribing practice (Table-3) 79% agreed that they refer to susceptibility pattern while treating for infections at their respective institution & 82% agreed that Micro lab results are efficiently communicated to treating physicians. In a study by Sivagnanam⁽¹²⁾ *etal* only 42% of practitioners agreed that they refer sensitivity reports. The necessity of De-escalation to oral antibiotics from IV is needed was agreed by 86% of clinicians.

As shown in Table-5, 74% of respondents disagreed for pharmacist's recommendation for Antibiotics. A similar data was shown in a study by Shah *etal*⁽²⁰⁾ wherein 73% respondents gave less importance for Pharmacists Recommendations.

Our institution organised a CME which emphasised problems of AMR, and how to combat Resistance by Basic infection control measures like Hand Hygiene, Antibiotic policy & Antibiotic stewardship .A post CME questionnaire survey was done to assess the transfer of knowledge which revealed that almost 100% agreed that basic infection control measures will reduce HCAI & there by Antibiotic resistance as shown in TABLE: 5. 100% of respondents agreed that they will be benefited by CME which will update them in AMR knowledge & Infection control practices. In a study by shah *etal* 70% agreed that CME will help in updating knowledge.

To our knowledge this is the first time Pre & Para clinical faculties were included in a KAP survey on Antibiotic resistance. This inclusion was done because many of the pre and Para clinical staffs are into General practise and also the necessity of AMR knowledge is essential while treating friends & families.

VI. CONCLUSION

Antimicrobial resistance accounts for numerous social & economic costs including mortality & morbidity. AMR continues to be a growing problem for all clinicians nationally & at institutional level. A multifaceted problem caused by AMR requires a multifaceted solution. At the institutional level, the assessment of clinician's knowledge on awareness about AMR and to educate them becomes a priority before initiating other strategies.

To summarise, our KAP study on Antibiotic resistance showed that though 95% of clinicians viewed this as a national problem, only 75% agreed that it's a problem in their institution. Also only 81% agreed that poor infection control measures & poor isolation precautions contributes to AMR and 79% refer to susceptibility pattern given by Micro lab. De-escalation of IV antibiotics to Oral antibiotics is a necessity was agreed by 86.5% of respondents.

Finally what have we learnt and understood was that the knowledge & attitude of clinician is crucial to reduce AMR at institutional level. Also as AMR problem is not limited by specialities, a better understanding of practices by all specialities included. Overall, most of our clinicians had better understanding and surprisingly Pre & Para clinical doctors also have enough knowledge regarding Antibiotics practice. Education by workshops & CME play a major role in updating knowledge. Following the study we have framed Antibiotics Policy and stewardship based on our institutional Antibio gram which addressed the susceptibility pattern of the most prevalent drug resistant pathogens.

VII. ACKNOWLEDGEMENT

The authors acknowledge all the clinicians & Pre and Para medical doctors who participated in this survey.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to leadership. *JAMA*. 1996; 275:234-240.
2. Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. *Infect Control Hosp Epidemiol*. 1996; 17:490-495.
3. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. *Infect Control Hosp Epidemiol*. 1997; 18:275-291.

4. Murthy R. Implementation of strategies to control antimicrobial resistance. *Chest*. 2001; 119 (suppl): 405S-411S.
5. World Health Organization. Editorial -- antimicrobial resistance: a global threat. *Essent Drugs Monit*. 2000; 28 & 29: Available at <http://www.who.int/medicines/library/monitor/EDM2829en.pdf>.
6. Ghafur, et al. "The Chennai declaration" Recommendations of "A roadmap- to tackle the challenge of antimicrobial resistance" – A joint meeting of medical societies of India. *Indian Journal of Cancer* |October–December 2012 : 49; 4:84-94
7. Step-by-Step Approach for Development and Implementation of Hospital Antibiotic Policy and Standard Treatment Guidelines. <http://apps.who.int/medicinedocs/en/m/abstract/Js19184en/>
8. Hospital antibiogram: A Necessity. *Indian J Med Microbial*. 2010 Oct-Dec; 28(4):277-80.
9. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. *Clin Infect Dis*. (2007) 44 (2): 159-177.
10. http://www.ncdc.gov.in/ab_policy.pdf
11. A Kapil. India needs an implementable antibiotic policy. *Indian J Med Microbial*: 2013; 31: 2; 111-113.
12. G Sivagnanametal. A Survey on Current Attitude of Practicing Physicians upon Usage of Antimicrobial Agents in Southern Part of India. *MedGenMed*. 2004; 6(2): 1.
13. Ambili Remesh, A.M Gayathri, Rohit Singh, K.G. Retnavally. The Knowledge, Attitude and the Perception of Prescribers on the Rational Use of Antibiotics and the Need for an Antibiotic Policy–A Cross Sectional Survey in a Tertiary Care Hospital. *Journal of Clinical and Diagnostic Research*. 2013 April, Vol-7(4): 675-679.
14. García et al. Knowledge, attitudes and practice survey about antimicrobial resistance and prescribing among physicians in a hospital setting in Lima, Peru. *BMC Clinical Pharmacology* 2011, 11:18.
15. Pulcini et al. Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. *Clin Microbiol Infect* 2011; 17: 80–87
16. Giblin, et al. Clinicians' Perceptions of the Problem of Antimicrobial Resistance in Health Care Facilities. *Arch Intern Med*. 2004; 164:1662-1668.
17. Survey of Infection Control, Antibiotic Stewardship and Occupational Health Resources in Irish Acute Hospitals SARI Hospital Survey 2003, Draft Report, November 2004.
18. Physicians from Various specialities concerning Antimicrobial use and resistance. *Arch Int medicine*. 2004; 164:1451-1456.
19. Mamoonetal. A point prevalence survey of antibiotic prescriptions: benchmarking and patterns of use. *Br J Clin Pharmacol* / 71:2 / 293–296 / 293
20. M. Salman Shah¹, Anees Ahmad¹, Riyaz Ahmad S, Najam Khalique, M. Athar Ansari¹. Emerging Antibiotic Resistance: A Reflection of Actual Practice among Doctors at Tertiary Care Hospitals. *Int.J.Curr. Microbiol.App.Sci* (2015) Special Issue-1: 127-133
21. Maha S. Eltwansy, Ghada M. Salem. Assessment of knowledge perception of resident doctors regarding antibiotic resistance and prescription practice at zigzag university hospital, 2013. *International journal of Basic and Applied sciences*.3(4)-2014 363-371
22. C. William Wester, MD; Lakshmi Durairaj, MD; Arthur T. Evans, MD, MPH; David N. Schwartz, MD; Shahid Husain, MD; Enrique Martinez, MD. Antibiotic Resistance: A Survey of Physician Perceptions. *Arch Intern Med*. 2002; 162(19):2210-2216.



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 15 Issue 4 Version 1.0 Year 2015
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Prevalence of Resistant Strains of *Streptococcus Pneumoniae* to Oxacillin, Ofloxacin and Rifampicin in Abraka South-South Nigeria

By Felix O. Enwa, Mercy I Iyamu, Christabel I Eboigbe & C O Esimone

Delta State University, Nigeria

Abstract- The clinical isolate *Streptococcus pneumoniae* is a major cause of illness such as pneumoniae, meningitis, bacteremia and otitis media in children and the elderly. The emergence of drug-resistant strains threatens to complicate the management of these diseases. An hospital-based and community-based surveillance for drug-resistant *Streptococcus pneumoniae* in outpatients with respiratory infection in Abraka, Delta State Nigeria was conducted. Between August – October 2014, a cross-sectional study was conducted in Abraka general hospital and Abraka community to assess the prevalence of drug resistant *Streptococcus pneumoniae* isolated from sputum samples of patients with cough and catarrh (respiratory tract infection). A total of 125 sputum samples of patients with respiratory tract infection were collected and inoculated on 5% sheep-blood agar, incubated at 35oC for 24hours in 5-10% CO₂. Susceptibility testing panels of Ofloxacin, Rifampicin and Oxacillin were tested against isolated *Streptococcus pneumoniae*. Of the 125 sputum samples collected 28 (22.4%) was positive for *Streptococcus pneumoniae*.

Keywords: pneumonia; resistance; susceptibility; prevalence.

GJMR-C Classification : NLMC Code: WC 202



Strictly as per the compliance and regulations of:



© 2015. Felix O. Enwa, Mercy I Iyamu, Christabel I Eboigbe & C O Esimone. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prevalence of Resistant Strains of *Streptococcus Pneumoniae* to Oxacillin, Ofloxacin and Rifampicin in Abraka South-South Nigeria

Felix O. Enwa ^α, Mercy I Iyamu ^σ, Christabel I Eboigbe ^ρ & C O Esimone ^ω

Abstract- The clinical isolate *Streptococcus pneumoniae* is a major cause of illness such as pneumoniae, meningitis, bacteremia and otitis media in children and the elderly. The emergence of drug-resistant strains threatens to complicate the management of these diseases. An hospital-based and community-based surveillance for drug-resistant *Streptococcus pneumoniae* in outpatients with respiratory infection in Abraka, Delta State Nigeria was conducted. Between August – October 2014, a cross-sectional study was conducted in Abraka general hospital and Abraka community to assess the prevalence of drug resistant *Streptococcus pneumoniae* isolated from sputum samples of patients with cough and catarrh (respiratory tract infection). A total of 125 sputum samples of patients with respiratory tract infection were collected and inoculated on 5% sheep-blood agar, incubated at 35°C for 24hours in 5-10% CO₂. Susceptibility testing panels of Ofloxacin, Rifampicin and Oxacillin were tested against isolated *Streptococcus pneumoniae*. Of the 125 sputum samples collected 28 (22.4%) was positive for *Streptococcus pneumoniae*. 18 out of 75male adults (24%) and 10 out of 50female adults (20%) were positive for *Streptococcus pneumoniae*. Also from the result, samples that were positive for *Streptococcus pneumoniae* when considered in terms of age group, showed that adults between 20-25 years had the highest prevalence rate of (31%) when compared to those in patients between 26 -30years which was (13%). Susceptibility studies showed that the highest resistance of *Streptococcus pneumoniae* was observed in the use of oxacillin and rifampicin which gave no zone of inhibition and highest sensitivity was observed in the use of ofloxacin with percentage inhibition 74.3%.

Keywords: pneumonia; resistance; susceptibility; prevalence.

I. INTRODUCTION

The discovery of antibiotics and their general use had transformed the patterns of disease and death in many countries (James, 2006 & Sekowska, 2002). Many diseases that once caused high mortality such as tuberculosis, pneumonia and septicaemia became controllable and surgical infections reduced. These successes could hardly be measured when clinical antimicrobial resistance emerged (knothe, 1983)

Author α ρ: Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Delta State University, PMB 1, Abraka, Delta State, Nigeria. e-mail: felixenwa@yahoo.com

Author σ: Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.

Author ω: Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, PMB 5025, Awka, Anambra State, Nigeria.

leading to treatment failures. But this antimicrobial resistance was to a single antibiotic at the time, so many researchers (Al-Jasser, 2006) are of the view that the appearance of multi drug resistant pathogens is a recent phenomenon, which has become a worldwide problem.

There are currently 90 known serotypes, with the ten most common causing greater than 60% of worldwide invasive disease (CDC, 2003a). *Streptococcus pneumoniae* is a normal inhabitant of the human upper respiratory tract. The bacterium can cause pneumoniae usually of the lobar type, paranasal sinusitis and otitismedia, or meningitis, *Streptococcus pneumoniae* is currently the leading cause of invasive bacteria disease in children and the elderly. Pneumonia is a disease of the lung that is caused by a variety of bacteria including *streptococcus*, *Staphylococcus*, *pseudomonas*, *Haemophilus*, *Chlamydia* and *Mycoplasma*, several viruses and certain fungi and protozoans. The disease may be divided into two forms; bronchial pneumonia is most prevalent in infants, young children and aged adults. It is caused by various bacteria, including *Streptococcus pneumonia* and Lobar pneumonia which is more common in younger adults. A majority (more than 80%) of the cases of lobar pneumonia are caused by *Streptococcus pneumoniae*, lobar pneumonia involves all of a single lobe of the lungs, wherein the entire areas of involvement tends to become a consolidated mass, in contrast to the spongy texture of lung tissue. (Kenneth, 2003).

Pneumococcal pneumonia is the most common form of pneumococcal infection in adults, and accounts for approximately 36% of community-acquired pneumonia and 50% of hospital-acquired pneumonia. The period of time from infection to presentation of signs and symptoms is short, lasting only one to three days. Mortality rates range from 5-7%, and may be higher in the elderly (CDC, 2003b).

Transmission of *Streptococcus pneumonia* occurs via respiratory droplets from healthy persons carrying the organism in the naso-pharynx or from person with pneumococcal disease. Following exposure, the organism may establish itself in the nasopharynx of its new host usually resulting in asymptomatic colonisation. The organism can be carried for a period of weeks to months. However

sometimes, the newly acquired pneumococcus evades host defensive mechanisms and causes illness (Buttleret *al* 1993).

Antibiotics from different classes can be used in treatment. These are chosen according to the host (age, allergy, localisation of the infection and the epidemiology of antibiotics resistance of pneumococcus strains). Aminopenicillins and penicillins are widely used for the treatment of pneumococcal infection and they are the first line anti-microbial in many countries to treat acute community acquired pneumonia. (Barlett, *et al.*, 2004). β -Lactam inhibits the peptidoglycan synthesis of the bacteria cell wall by forming a covalent bond with the active site of penicillin-binding proteins leading to hydrolysis of the bacteria. Mutations results in a decrease affinity to β -lactam. With the widespread use of antibiotics, starting in the 1940s with penicillin, there has been a steady rise in the number of resistant serotypes or strains of drug resistant *Streptococcus pneumoniae*. The first clinical diagnosis of penicillin-resistant *S. pneumoniae* appeared in the 1967 in New Guinea, and multi-drug resistant strains appeared in South Africa in 1977 (Tomasz, 1997).

The CDC reports that annually there are an estimated 175,000 hospitalized cases of *pneumococcal pneumonia*, 50,000 cases of *pneumococcal bacteremia* and 3,000-6,000 cases of pneumococcal meningitis (CDC, 2003a). Additionally in children less than 5 years there are estimated 5 million case of otitis media every year in this country. Due to the severity of the disease caused by invasive *S. pneumoniae* and the continued rise of antibiotic resistance, several vaccines have been developed in the United State.

The increasing prevalence of resistance to established antibiotics among key bacterial respiratory tract pathogens such as *Streptococcus pneumonia* is a major healthcare problem in Delta State. However, the increasing prevalence of antibiotics resistance bacterial therefore poses a significant problem in selection of drug of choice for treatment of the infection.

Amazingly, the phenomenon of bacteria resistance is now threatening to take us back to a pre-antibiotics era. It has been reported that the growing phenomenon of antibiotics resistance is caused by the use and abuse of antibiotics.

The overall aim of study is to investigate the prevalence of resistance strains of *Streptococcus pneumoniae* to *oxacillin*, *ofloxacin* and *rifampicin* (fluoroquinolones) and contribute to the existing body of knowledge on the antimicrobial efficacy of antibiotics against the bacteria.

II. MATERIALS AND METHODS

a) Collection of clinical specimen (sputum)

Specimen collection was carried out from august to October 2014, a total of 125 sputum samples

of adults with upper respiratory tract infection in Abraka was collected. The sputum samples were collected from patients with symptoms of lower respiratory tract infection especially cough and who was clinically diagnosed of having respiratory tract infection. A sterile flexible swab was inserted into the patient's nostrils until it touches the posterior wall of the nasopharynx. After performing rotator movements for 5seconds so that secretion could be absorbed, the swab was removed and submerged on Amies medium without charcoal and taken to the microbiology laboratory at room temperature. A single collection was performed for each patient.

b) Isolation of streptococcus pneumonia from sputum samples

Sputum samples was streaked onto nutrient agar plate and incubated at 35-37°C for 24hours and plates that showed growth of organism was further plated on blood agar prepared with tryptose blood agar base (Difco, Becton Dickson and company, sparks MD USA) Supplement with 5% of defibrinated sheep blood.

c) Identification of test micro-organism

The identification of the test organisms by appropriate cultural methods and gram staining was done following standard microbiological procedures.

d) Biochemical reactions

i. Bile solubility test

1. Preparation of Bile salt

2% bile salt was prepared by dissolving 2g in 100mls of sterilized normal saline, making a solution of bile salt.

2. Inoculum preparation

Bacterial inoculum was prepared by inoculating 0.25mls of 24hours overnight culture into sterilized test tubes.

0.25mls of the bile salt was added into broth test tube. 0.25mls of normal saline was dispensed into another test tube to serve as the control. 0.25mls of broth organism was added into both test tubes and incubated for 2hours. A clear solution indicated a positive test for *Streptococcus pneumonia*.

e) Susceptibility studies

Susceptibility testing panels that include antibiotics used in treating patients with pneumonia in Abraka which includes Ofloxacin, Rifampicin and Oxacillin were treated against isolated strains of *Streptococcus pneumonia* using disc diffusion method.

Briefly a Mueller-Hinton agar plate was prepared following manufacturer's instruction, test organisms equivalent to 0.5 Mcfarlane equivalent standard was inoculated on the surface of sterile agar plate and was allowed for 15mins to prediffuse, then antibiotics disc as mentioned above was placed on the

agar plates with sterile forceps and incubated for 18-24 hours at 37°C after which the inhibition zone diameter was taken in millimetres. Susceptibility result was interpreted as resistance or susceptible or intermediate according to the definitions of the national committee for clinical and laboratory standard institutes.

Other biochemical tests such as Carbohydrate Fermentation, Iodine and Coagulase were carried out as described by Monica 2002.

III. RESULTS

a) Identification of collected test micro-organisms

The identification test carried out on the clinical isolates as presented in Table 3.1 showed that *Streptococcus pneumoniae* presented a characteristic alpha haemolytic reaction (greenish zone of inhibition) on blood agar which differentiates *Streptococcus*

pneumonia from the group A (beta haemolytic) *Streptococcus*, but not from commercial alpha haemolytic (viridans).

Motility test results showed that *Streptococcus pneumoniae* is non-motile. Catalase test results showed that they are catalase negative (they lack catalase) and fermentation test result showed they ferment glucose to lactic acid. Gram-staining reaction test results showed that they are gram positive showing a lancet shaped cocci (elongated cocci with a slightly pointed outer curvature), they were seen as pairs of cocci (diplococci) but they also occur singly and in short chains.

In bile testing, results showed that they undergo lysis by bile salt (eg deoxycholate). Virtually all clinical isolates of pneumococci harbour the autolysin and undergo deoxycholate lysis.

Table 3.1: Results of identification

	Identification Tests	Results
1	Cultural Characteristics	Colonies produce a zone of green (alpha) haemolysis when cultured on blood agar. They grow as glistening colonies on agar about 1mm in diameter
2	Motility Tests	They are non-motile
3	Staining Reactions	They appear as dark purple gram positive cocci occurring in pairs, singly or short chains.
4	Biochemical Reactions	
i	Coagulase	Negative (They lack coagulase)
ii	Indole	Negative (They lack indole)
iii	Sugar Fermentation	Show a yellow colour with bubbles in a tube (they ferment glucose to lactic acid).
5	Bile Solubility Test	Show a clear solution in the tube containing 2.5ml of bile salt and 2.5ml of broth culture of organism.

b) Antimicrobial sensitivity test results

i. Population of streptococcus pneumoniae isolated

From Table II, the prevalence rate of *Streptococcus pneumoniae* carries among the adult studied was 22.4% (28/125). Eighteen out of seventy-five male adult (24%) and 10 out of 50 female adults (20%) had positive cultures for *Streptococcus pneumoniae*.

A significant difference was found when the positive result of pneumococcal isolation was arranged according to age group ($p=0.0005$), with a higher rate of isolation in the adult aged from 20 – 25 years (31%; 20/65). Among 40 adults, from 26 – 30 years old (13%, 8/60) had positive cultures for pneumococcus. 60 patients were treated with antimicrobial drugs in the last month with a higher rate of isolation is (25%).

Table 3.2 : Association of epidemiological data with the isolation of *streptococcus pneumoniae* of 125 adults studied

Variable	Negativity, N (%)	Positive, P (%)
Population	97 (77.6%)	28 (22.4%)
Sex		
Female	40 (80%)	10 (20%)
Male	57 (76%)	18 (24%)
Age		
20 – 25 Years	45 (69%)	20 (31%)
26 – 30 Years	52 (86%)	8 (13%)
Use of Antibiotics (prior to sputum collection)		
No		
Yes	34 (84%)	10 (16%)
Not Reported	45 (75%)	15 (25%)
	18 (86%)	3 (14%)

c) *Antimicrobial sensitivity result*

The results of penicillin susceptibility tests of pneumococci using rifampicin and oxacillin, determined that of 28 specimens of confirmed *Streptococcus pneumoniae* all were resistant to rifampicin and oxacillin. All isolates were sensitive to ofloxacin which gave a mean zone of inhibition of 18.68 and standard deviation of 2.75 (18.68 \pm 2.75) with percentage inhibition of 74.3%.

IV. DISCUSSION

The result obtained in the present study described the epidemiology period in Abraka, Delta state where the prevalence of adults colonized with nasopharyngeal *Streptococcus pneumoniae* was 22.4% from which 24% male adults and 20% female adults are for *Streptococcus pneumoniae*. This study confirmed that age is an important factor for pneumococcal isolation with high prevalence of isolates in the age group between 20-25 years (31%) and low prevalence of isolates in the age group between 26-30 years (13%) which is agreement with Austrian (1986).

According to Borer *et al.* 2001, the alterations in the mucosa of the respiratory tract of allergic patients can result in impaired mucociliary activity, predisposing to bacteria colonization in this site. The interpretation of susceptibility of the drugs used in this study showed that pneumococcal resistance rate was higher with rifampicin and oxacillin as they showed no zone of inhibition indicating no susceptibility and a high susceptibility (74.3%) was observed in ofloxacin.

Previous antibiotic exposure has been documented as a risk factor for antibiotic resistance in many studies and also, antibiotic therapy may increase the rate of isolation of penicillin-resistant nasopharyngeal pneumococci (Kaplan and Mason 1998). This fact may explain the high prevalence of oxacillin resistant pneumococcal strains found in this study, since 60(48%) of the 125 adults had been treated with antimicrobial drugs in the month prior to the study.

The high rate of resistance to rifampicin and oxacillin found in this study is similar to that described in other studies in and outside Nigeria (Jacobs *et al.*, 1978).

Ofloxacin can be used as an alternate drug of choice in the treatment of *Streptococcus pneumoniae* infections, although the optional therapy for infections with drug-resistant pneumococci is not well defined.

There are reports that children 6years of age were more likely than older children and adults to be infected with multi-resistant isolates. However in this study, a disturbingly high incidence of drug resistant pneumococcal infections among adults was found.

Although the overall prevalence of pneumococcal infections in Abraka community is low 22.4% recommendations for empirical therapy are

needed particularly in communities in which the prevalence of drug resistant is high. The geographic variation in the prevalence of drug resistant strains of pneumococci in Nigeria highlights the importance of community based monitoring of pneumococcal susceptibility to antimicrobial agents to guide therapy. In addition, the increased prevalence of drug resistant *Streptococcus pneumoniae* emphasizes the critical need for preventive strategies in populations at risk from serious pneumococcal infections.

Frequent and prophylactic use of antimicrobial drugs has also been associated with a risk of drug resistant pneumococcal infections and such was observed in this study of 125 adult sputum collected 44 adults had not been treated with antibiotics prior to the collection while 60 adults had been treated and 21 adult cases not reported. A significant difference was observed with adults who had been treated with antibiotics prior to sputum collection and those who had not been treated. Of the 28 *Streptococcal pneumonia* isolated, 15 (25%) out of 60 adults who had had antibiotics prior to collection was positive for *Streptococcus pneumonia* while 10 out of 44 adults who had not had antibiotic prior to collection of sputum were positive. (10; 16%). Despite a low incidence of pneumococcal infection in Abraka especially in patients between the ages of 26 – 31 years, age groups of 20 – 31 years was found to be associated with drug-resistant *Streptococcus pneumoniae*. Rural residence and poverty may be responsible for poor health states and little or no access to medical care. As a result, people tend to see the roadside chemist/pharmacy dealers and procure cheap drugs without doctor's prescription because there is no restriction or guidelines to the use of antibiotics in Nigeria. A critical component for the control of drug-resistant *Streptococcus pneumoniae* will be community wide educational programs for clinicians and the public on the importance of appropriate antibiotic use.

The vast majority of *Streptococcus pneumoniae* isolates had a relatively high resistant to rifampicin and oxacillin. The continuing spread of drug resistant strains of pneumococci treatment options will become more limited and prevention measures will become critical.

From this study, possible reasons for this low prevalence in populations infected with *Streptococcus pneumonia*, include the fact that the survey only adults, the subjects were enrolled for a very short time, winter (a period of frequent respiratory illness) was not the season of enrolment, and the fact that human genetic traits may play a role.

The identification and confirmatory tests carried out on the organism to establish their identity yielded results that were in agreement with previous studies. For example *Streptococcus pneumonia* appeared as alpha haemolytic when cultured in blood agar, colonies characteristically produced an alpha (green) hemolysis.

Solubility in bile salt agar solution, also in agreement with previous studies, *Streptococcus pneumoniae* fermented glucose producing acid and gas, were coagulase negative and purple gram-positive cocci in clusters and single when viewed from the microscope.

Antimicrobial susceptible test is an essential technique used in pharmacology to determine the efficacy of novel antimicrobial agent against micro-organism.

Susceptibility studies was carried out using oxacillin, rifampicin and ofloxacin against isolated strains of *Streptococcus pneumoniae*. The experiment was replicated twice and an average zone of inhibition reading was taken. Studies were conducted to investigate the prevalence of *Streptococcus pneumoniae* infection in adults in Abraka community and also to investigate the prevalence of resistance of *Streptococcus pneumoniae* to oxacillin, rifampicin and ofloxacin and to know the potential of these listed drugs as a broad spectrum antimicrobial agent in the treatment of nasopharyngeal infection.

The data collected were subjected to analysis, mean deviation, standard deviation and percentage deviation of the zones of inhibition exhibited by ofloxacin as no zone of inhibition was observed with rifampicin and oxacillin indicating non-sensitivity towards *Streptococcus pneumoniae*. This study emphasizes the importance of antimicrobial susceptibility testing of all *Streptococcus pneumoniae* infection in adults in Abraka, as well as crucial need for community based programs of surveillance for drug resistant pneumococcus to aid clinicians in their choice of therapy for pneumococcal infections.

From the study the following conclusion can be drawn;

The overall prevalence of *Streptococcus pneumoniae* infection in Abraka community is low.

- The standard antimicrobial agent ofloxacin was significantly more effective than rifampicin and oxacillin.
- Rifampicin and oxacillin antibiotics are not sensitive to *Streptococcus pneumoniae* as the bacteria were totally resistant.
- The study data suggest an urgent need for consensus guidelines to prevent development of multi-drug resistant strains of *Streptococcus pneumoniae* in this region in future.
- The prevalence of fluoroquinolone resistance in *Streptococcus pneumoniae* is low.

V. RECOMMENDATION

From the result obtained the following recommendations are made;

- Ofloxacin should be used as a first-line drug alone or in combination to treat pneumococcal infection

as well as infection of the upper respiratory tract in Abraka metropolis.

- Strategies to encourage judicious antibiotics use should be implemented this will enhance prevention of infections with *Streptococcus pneumoniae*.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Al-Jasser AM (2006). Stenotrophomonas maltophilia resistant to trimethoprim sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 5:23-26.
2. Austrian R.. (1986). Some aspects of the pneumococcal carrier state. J Antimicrob Chemother. ;18 Suppl A:35-45.
3. Barlett, J.G., R.F. Breiman, L.A. Mandell and T.M. File, Jr., (1998). Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin. Infect. Dis., 26: 811-838. PMID: 956.
4. Borer A, Meirson H, Peled N, Porat N, Dagan R, Fraser D.,(2001). Antibiotic-resistant pneumococci carried by young children do not appear to disseminate to adult members of a closed community. ClinInfectImmun.; 33: 436-44.
5. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR: (1993). Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. J Am Med Assoc, 270: 1826-1831.
6. CDC. (2003a). Active Bacteria Core Surveillance <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu01.pdf>. Retrieved Accessed November 23, 2003, from <http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu01.pdf>
7. CDC. (2003b, February 21, 2003). Epidemiology and Prevention of Vaccine-Preventable Diseases
8. *The pink book*. Retrived 1/11/04, 2004, from <http://www.cdc.gov/nip/publications/pink/default.ht>.
9. Kaplan, S.L. and E.O Mason, Jr.,(1998). Management of infections due to antibiotic-resistant *Streptococcus pneumoniae*. Clin. Microbiol. Rev., 11: 628-644. PMID: 9767060.
10. Knothe, H., Shah, P., Krcmery, V., Antal, M., Mitsuhashi, S., (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiellapneumoniae and Serratiamarcescens. Infection 11, 315–317.
11. James J. Rahal (2006). Novel Antibiotic Combinations against Infections with Almost Completely Resistant Pseudomonas aeruginosa and Acinetobacter Species. Journal of Clinical Infectious Diseases. Vol 43 Issue 2 Pages 595-599
12. Sekowska A, Janicka G, Kuzejko C, Wojda M, Wróblewski M, Szymankiewicz M (2002). Resistance of Klebsiella pneumonia strains producing and not producing ESBL (extended-spectrum betalactam-

ase) type enzymes to selected non-beta-lactam antibiotics. Med. Sci. Monit. 8(3): BR100-104.

13. Monica Cheesbrough (2004). District laboratory practice in tropical countries part 2. Antimicrobial sensitivity testing, Cambridge University low price edition, 141-142 pp. printed in Hong Kong by shek way Tong printing press ltd).



GLOBAL JOURNALS INC. (US) GUIDELINES HANDBOOK 2015

WWW.GLOBALJOURNALS.ORG

FELLOWS

FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards "FARSM" title to individuals. The 'FARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.



- The "FARSM" is a dignified title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add 'FARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and reputation to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

The following benefits can be availed by you only for next three years from the date of certification:



FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.



You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.


We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.





The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. johnhall@globaljournals.org. This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.



The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website <https://associationofresearch.org> which will be helpful to upgrade the dignity.



The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.



The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.





The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.



MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARSM)

The ' MARSM ' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.



MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

The following benefits can be availed by you only for next three years from the date of certification.



MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. johnhall@globaljournals.org. This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.





We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.

The MARS member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.



Once you are designated as MARS, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.



AUXILIARY MEMBERSHIPS

Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).

The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.



The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

The Institute will be entitled to following benefits:



The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA) The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.



The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.

The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.



Journals Research
inducing researches

The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.



We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf. The board can also take up the additional allied activities for betterment after our consultation.

The following entitlements are applicable to individual Fellows:

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.



Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals : Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50% E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15 % benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.



We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth \$ 2376 USD.

Other:

The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.



- In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10% discount if one is co-author or main author among group of authors.
- The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.
- The Fellow can become member of Editorial Board Member after completing 3yrs.
- The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.
- Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)
- • This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in-depth understanding of the application of suitable techniques to a particular area of research practice.

Note :

//

- In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.
- In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.
- In case of “Difference of Opinion [if any]” among the Board members, our decision will be final and binding to everyone.

//



PROCESS OF SUBMISSION OF RESEARCH PAPER

The Area or field of specialization may or may not be of any category as mentioned in 'Scope of Journal' menu of the GlobalJournals.org website. There are 37 Research Journal categorized with Six parental Journals GJCST, GJMR, GJRE, GJMBR, GJSFR, GJHSS. For Authors should prefer the mentioned categories. There are three widely used systems UDC, DDC and LCC. The details are available as 'Knowledge Abstract' at Home page. The major advantage of this coding is that, the research work will be exposed to and shared with all over the world as we are being abstracted and indexed worldwide.

The paper should be in proper format. The format can be downloaded from first page of 'Author Guideline' Menu. The Author is expected to follow the general rules as mentioned in this menu. The paper should be written in MS-Word Format (*.DOC,*.DOCX).

The Author can submit the paper either online or offline. The authors should prefer online submission.Online Submission: There are three ways to submit your paper:

(A) (I) First, register yourself using top right corner of Home page then Login. If you are already registered, then login using your username and password.

(II) Choose corresponding Journal.

(III) Click 'Submit Manuscript'. Fill required information and Upload the paper.

(B) If you are using Internet Explorer, then Direct Submission through Homepage is also available.

(C) If these two are not convenient, and then email the paper directly to dean@globaljournals.org.

Offline Submission: Author can send the typed form of paper by Post. However, online submission should be preferred.



PREFERRED AUTHOR GUIDELINES

MANUSCRIPT STYLE INSTRUCTION (Must be strictly followed)

Page Size: 8.27" X 11"

- Left Margin: 0.65
- Right Margin: 0.65
- Top Margin: 0.75
- Bottom Margin: 0.75
- Font type of all text should be Swis 721 Lt BT.
- Paper Title should be of Font Size 24 with one Column section.
- Author Name in Font Size of 11 with one column as of Title.
- Abstract Font size of 9 Bold, "Abstract" word in Italic Bold.
- Main Text: Font size 10 with justified two columns section
- Two Column with Equal Column with of 3.38 and Gaping of .2
- First Character must be three lines Drop capped.
- Paragraph before Spacing of 1 pt and After of 0 pt.
- Line Spacing of 1 pt
- Large Images must be in One Column
- Numbering of First Main Headings (Heading 1) must be in Roman Letters, Capital Letter, and Font Size of 10.
- Numbering of Second Main Headings (Heading 2) must be in Alphabets, Italic, and Font Size of 10.

You can use your own standard format also.

Author Guidelines:

1. General,
2. Ethical Guidelines,
3. Submission of Manuscripts,
4. Manuscript's Category,
5. Structure and Format of Manuscript,
6. After Acceptance.

1. GENERAL

Before submitting your research paper, one is advised to go through the details as mentioned in following heads. It will be beneficial, while peer reviewer justify your paper for publication.

Scope

The Global Journals Inc. (US) welcome the submission of original paper, review paper, survey article relevant to the all the streams of Philosophy and knowledge. The Global Journals Inc. (US) is parental platform for Global Journal of Computer Science and Technology, Researches in Engineering, Medical Research, Science Frontier Research, Human Social Science, Management, and Business organization. The choice of specific field can be done otherwise as following in Abstracting and Indexing Page on this Website. As the all Global

Journals Inc. (US) are being abstracted and indexed (in process) by most of the reputed organizations. Topics of only narrow interest will not be accepted unless they have wider potential or consequences.

2. ETHICAL GUIDELINES

Authors should follow the ethical guidelines as mentioned below for publication of research paper and research activities.

Papers are accepted on strict understanding that the material in whole or in part has not been, nor is being, considered for publication elsewhere. If the paper once accepted by Global Journals Inc. (US) and Editorial Board, will become the copyright of the Global Journals Inc. (US).

Authorship: The authors and coauthors should have active contribution to conception design, analysis and interpretation of findings. They should critically review the contents and drafting of the paper. All should approve the final version of the paper before submission

The Global Journals Inc. (US) follows the definition of authorship set up by the Global Academy of Research and Development. According to the Global Academy of R&D authorship, criteria must be based on:

- 1) Substantial contributions to conception and acquisition of data, analysis and interpretation of the findings.
- 2) Drafting the paper and revising it critically regarding important academic content.
- 3) Final approval of the version of the paper to be published.

All authors should have been credited according to their appropriate contribution in research activity and preparing paper. Contributors who do not match the criteria as authors may be mentioned under Acknowledgement.

Acknowledgements: Contributors to the research other than authors credited should be mentioned under acknowledgement. The specifications of the source of funding for the research if appropriate can be included. Suppliers of resources may be mentioned along with address.

Appeal of Decision: The Editorial Board's decision on publication of the paper is final and cannot be appealed elsewhere.

Permissions: It is the author's responsibility to have prior permission if all or parts of earlier published illustrations are used in this paper.

Please mention proper reference and appropriate acknowledgements wherever expected.

If all or parts of previously published illustrations are used, permission must be taken from the copyright holder concerned. It is the author's responsibility to take these in writing.

Approval for reproduction/modification of any information (including figures and tables) published elsewhere must be obtained by the authors/copyright holders before submission of the manuscript. Contributors (Authors) are responsible for any copyright fee involved.

3. SUBMISSION OF MANUSCRIPTS

Manuscripts should be uploaded via this online submission page. The online submission is most efficient method for submission of papers, as it enables rapid distribution of manuscripts and consequently speeds up the review procedure. It also enables authors to know the status of their own manuscripts by emailing us. Complete instructions for submitting a paper is available below.

Manuscript submission is a systematic procedure and little preparation is required beyond having all parts of your manuscript in a given format and a computer with an Internet connection and a Web browser. Full help and instructions are provided on-screen. As an author, you will be prompted for login and manuscript details as Field of Paper and then to upload your manuscript file(s) according to the instructions.



To avoid postal delays, all transaction is preferred by e-mail. A finished manuscript submission is confirmed by e-mail immediately and your paper enters the editorial process with no postal delays. When a conclusion is made about the publication of your paper by our Editorial Board, revisions can be submitted online with the same procedure, with an occasion to view and respond to all comments.

Complete support for both authors and co-author is provided.

4. MANUSCRIPT'S CATEGORY

Based on potential and nature, the manuscript can be categorized under the following heads:

Original research paper: Such papers are reports of high-level significant original research work.

Review papers: These are concise, significant but helpful and decisive topics for young researchers.

Research articles: These are handled with small investigation and applications

Research letters: The letters are small and concise comments on previously published matters.

5. STRUCTURE AND FORMAT OF MANUSCRIPT

The recommended size of original research paper is less than seven thousand words, review papers fewer than seven thousands words also. Preparation of research paper or how to write research paper, are major hurdle, while writing manuscript. The research articles and research letters should be fewer than three thousand words, the structure original research paper; sometime review paper should be as follows:

Papers: These are reports of significant research (typically less than 7000 words equivalent, including tables, figures, references), and comprise:

- (a) Title should be relevant and commensurate with the theme of the paper.
- (b) A brief Summary, "Abstract" (less than 150 words) containing the major results and conclusions.
- (c) Up to ten keywords, that precisely identifies the paper's subject, purpose, and focus.
- (d) An Introduction, giving necessary background excluding subheadings; objectives must be clearly declared.
- (e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition; sources of information must be given and numerical methods must be specified by reference, unless non-standard.
- (f) Results should be presented concisely, by well-designed tables and/or figures; the same data may not be used in both; suitable statistical data should be given. All data must be obtained with attention to numerical detail in the planning stage. As reproduced design has been recognized to be important to experiments for a considerable time, the Editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned un-refereed;
- (g) Discussion should cover the implications and consequences, not just recapitulating the results; conclusions should be summarizing.
- (h) Brief Acknowledgements.
- (i) References in the proper form.

Authors should very cautiously consider the preparation of papers to ensure that they communicate efficiently. Papers are much more likely to be accepted, if they are cautiously designed and laid out, contain few or no errors, are summarizing, and be conventional to the approach and instructions. They will in addition, be published with much less delays than those that require much technical and editorial correction.



The Editorial Board reserves the right to make literary corrections and to make suggestions to improve brevity.

It is vital, that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

Format

Language: The language of publication is UK English. Authors, for whom English is a second language, must have their manuscript efficiently edited by an English-speaking person before submission to make sure that, the English is of high excellence. It is preferable, that manuscripts should be professionally edited.

Standard Usage, Abbreviations, and Units: Spelling and hyphenation should be conventional to The Concise Oxford English Dictionary. Statistics and measurements should at all times be given in figures, e.g. 16 min, except for when the number begins a sentence. When the number does not refer to a unit of measurement it should be spelt in full unless, it is 160 or greater.

Abbreviations supposed to be used carefully. The abbreviated name or expression is supposed to be cited in full at first usage, followed by the conventional abbreviation in parentheses.

Metric SI units are supposed to generally be used excluding where they conflict with current practice or are confusing. For illustration, 1.4 l rather than $1.4 \times 10^{-3} \text{ m}^3$, or 4 mm somewhat than $4 \times 10^{-3} \text{ m}$. Chemical formula and solutions must identify the form used, e.g. anhydrous or hydrated, and the concentration must be in clearly defined units. Common species names should be followed by underlines at the first mention. For following use the generic name should be constricted to a single letter, if it is clear.

Structure

All manuscripts submitted to Global Journals Inc. (US), ought to include:

Title: The title page must carry an instructive title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) wherever the work was carried out. The full postal address in addition with the e-mail address of related author must be given. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining and indexing.

Abstract, used in Original Papers and Reviews:

Optimizing Abstract for Search Engines

Many researchers searching for information online will use search engines such as Google, Yahoo or similar. By optimizing your paper for search engines, you will amplify the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in a further work. Global Journals Inc. (US) have compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

Key Words

A major linchpin in research work for the writing research paper is the keyword search, which one will employ to find both library and Internet resources.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy and planning a list of possible keywords and phrases to try.

Search engines for most searches, use Boolean searching, which is somewhat different from Internet searches. The Boolean search uses "operators," words (and, or, not, and near) that enable you to expand or narrow your affords. Tips for research paper while preparing research paper are very helpful guideline of research paper.

Choice of key words is first tool of tips to write research paper. Research paper writing is an art. A few tips for deciding as strategically as possible about keyword search:



- One should start brainstorming lists of possible keywords before even begin searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in research paper?" Then consider synonyms for the important words.
- It may take the discovery of only one relevant paper to let steer in the right keyword direction because in most databases, the keywords under which a research paper is abstracted are listed with the paper.
- One should avoid outdated words.

Keywords are the key that opens a door to research work sources. Keyword searching is an art in which researcher's skills are bound to improve with experience and time.

Numerical Methods: Numerical methods used should be clear and, where appropriate, supported by references.

Acknowledgements: Please make these as concise as possible.

References

References follow the Harvard scheme of referencing. References in the text should cite the authors' names followed by the time of their publication, unless there are three or more authors when simply the first author's name is quoted followed by et al. unpublished work has to only be cited where necessary, and only in the text. Copies of references in press in other journals have to be supplied with submitted typescripts. It is necessary that all citations and references be carefully checked before submission, as mistakes or omissions will cause delays.

References to information on the World Wide Web can be given, but only if the information is available without charge to readers on an official site. Wikipedia and Similar websites are not allowed where anyone can change the information. Authors will be asked to make available electronic copies of the cited information for inclusion on the Global Journals Inc. (US) homepage at the judgment of the Editorial Board.

The Editorial Board and Global Journals Inc. (US) recommend that, citation of online-published papers and other material should be done via a DOI (digital object identifier). If an author cites anything, which does not have a DOI, they run the risk of the cited material not being noticeable.

The Editorial Board and Global Journals Inc. (US) recommend the use of a tool such as Reference Manager for reference management and formatting.

Tables, Figures and Figure Legends

Tables: Tables should be few in number, cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g. Table 4, a self-explanatory caption and be on a separate sheet. Vertical lines should not be used.

Figures: Figures are supposed to be submitted as separate files. Always take in a citation in the text for each figure using Arabic numbers, e.g. Fig. 4. Artwork must be submitted online in electronic form by e-mailing them.

Preparation of Electronic Figures for Publication

Even though low quality images are sufficient for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit (or e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings) in relation to the imitation size. Please give the data for figures in black and white or submit a Color Work Agreement Form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution (at final image size) ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs) : >350 dpi; figures containing both halftone and line images: >650 dpi.



Color Charges: It is the rule of the Global Journals Inc. (US) for authors to pay the full cost for the reproduction of their color artwork. Hence, please note that, if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a color work agreement form before your paper can be published.

Figure Legends: Self-explanatory legends of all figures should be incorporated separately under the heading 'Legends to Figures'. In the full-text online edition of the journal, figure legends may possibly be truncated in abbreviated links to the full screen version. Therefore, the first 100 characters of any legend should notify the reader, about the key aspects of the figure.

6. AFTER ACCEPTANCE

Upon approval of a paper for publication, the manuscript will be forwarded to the dean, who is responsible for the publication of the Global Journals Inc. (US).

6.1 Proof Corrections

The corresponding author will receive an e-mail alert containing a link to a website or will be attached. A working e-mail address must therefore be provided for the related author.

Acrobat Reader will be required in order to read this file. This software can be downloaded

(Free of charge) from the following website:

www.adobe.com/products/acrobat/readstep2.html. This will facilitate the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.

Proofs must be returned to the dean at dean@globaljournals.org within three days of receipt.

As changes to proofs are costly, we inquire that you only correct typesetting errors. All illustrations are retained by the publisher. Please note that the authors are responsible for all statements made in their work, including changes made by the copy editor.

6.2 Early View of Global Journals Inc. (US) (Publication Prior to Print)

The Global Journals Inc. (US) are enclosed by our publishing's Early View service. Early View articles are complete full-text articles sent in advance of their publication. Early View articles are absolute and final. They have been completely reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after sending them. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the conventional way.

6.3 Author Services

Online production tracking is available for your article through Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The authors will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript.

6.4 Author Material Archive Policy

Please note that if not specifically requested, publisher will dispose off hardcopy & electronic information submitted, after the two months of publication. If you require the return of any information submitted, please inform the Editorial Board or dean as soon as possible.

6.5 Offprint and Extra Copies

A PDF offprint of the online-published article will be provided free of charge to the related author, and may be distributed according to the Publisher's terms and conditions. Additional paper offprint may be ordered by emailing us at: editor@globaljournals.org .



Before start writing a good quality Computer Science Research Paper, let us first understand what is Computer Science Research Paper? So, Computer Science Research Paper is the paper which is written by professionals or scientists who are associated to Computer Science and Information Technology, or doing research study in these areas. If you are novel to this field then you can consult about this field from your supervisor or guide.

TECHNIQUES FOR WRITING A GOOD QUALITY RESEARCH PAPER:

1. Choosing the topic: In most cases, the topic is searched by the interest of author but it can be also suggested by the guides. You can have several topics and then you can judge that in which topic or subject you are finding yourself most comfortable. This can be done by asking several questions to yourself, like Will I be able to carry our search in this area? Will I find all necessary recourses to accomplish the search? Will I be able to find all information in this field area? If the answer of these types of questions will be "Yes" then you can choose that topic. In most of the cases, you may have to conduct the surveys and have to visit several places because this field is related to Computer Science and Information Technology. Also, you may have to do a lot of work to find all rise and falls regarding the various data of that subject. Sometimes, detailed information plays a vital role, instead of short information.

2. Evaluators are human: First thing to remember that evaluators are also human being. They are not only meant for rejecting a paper. They are here to evaluate your paper. So, present your Best.

3. Think Like Evaluators: If you are in a confusion or getting demotivated that your paper will be accepted by evaluators or not, then think and try to evaluate your paper like an Evaluator. Try to understand that what an evaluator wants in your research paper and automatically you will have your answer.

4. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

5. Ask your Guides: If you are having any difficulty in your research, then do not hesitate to share your difficulty to your guide (if you have any). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work then ask the supervisor to help you with the alternative. He might also provide you the list of essential readings.

6. Use of computer is recommended: As you are doing research in the field of Computer Science, then this point is quite obvious.

7. Use right software: Always use good quality software packages. If you are not capable to judge good software then you can lose quality of your paper unknowingly. There are various software programs available to help you, which you can get through Internet.

8. Use the Internet for help: An excellent start for your paper can be by using the Google. It is an excellent search engine, where you can have your doubts resolved. You may also read some answers for the frequent question how to write my research paper or find model research paper. From the internet library you can download books. If you have all required books make important reading selecting and analyzing the specified information. Then put together research paper sketch out.

9. Use and get big pictures: Always use encyclopedias, Wikipedia to get pictures so that you can go into the depth.

10. Bookmarks are useful: When you read any book or magazine, you generally use bookmarks, right! It is a good habit, which helps to not to lose your continuity. You should always use bookmarks while searching on Internet also, which will make your search easier.

11. Revise what you wrote: When you write anything, always read it, summarize it and then finalize it.



12. Make all efforts: Make all efforts to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in introduction, that what is the need of a particular research paper. Polish your work by good skill of writing and always give an evaluator, what he wants.

13. Have backups: When you are going to do any important thing like making research paper, you should always have backup copies of it either in your computer or in paper. This will help you to not to lose any of your important.

14. Produce good diagrams of your own: Always try to include good charts or diagrams in your paper to improve quality. Using several and unnecessary diagrams will degrade the quality of your paper by creating "hotchpotch." So always, try to make and include those diagrams, which are made by your own to improve readability and understandability of your paper.

15. Use of direct quotes: When you do research relevant to literature, history or current affairs then use of quotes become essential but if study is relevant to science then use of quotes is not preferable.

16. Use proper verb tense: Use proper verb tenses in your paper. Use past tense, to present those events that happened. Use present tense to indicate events that are going on. Use future tense to indicate future happening events. Use of improper and wrong tenses will confuse the evaluator. Avoid the sentences that are incomplete.

17. Never use online paper: If you are getting any paper on Internet, then never use it as your research paper because it might be possible that evaluator has already seen it or maybe it is outdated version.

18. Pick a good study spot: To do your research studies always try to pick a spot, which is quiet. Every spot is not for studies. Spot that suits you choose it and proceed further.

19. Know what you know: Always try to know, what you know by making objectives. Else, you will be confused and cannot achieve your target.

20. Use good quality grammar: Always use a good quality grammar and use words that will throw positive impact on evaluator. Use of good quality grammar does not mean to use tough words, that for each word the evaluator has to go through dictionary. Do not start sentence with a conjunction. Do not fragment sentences. Eliminate one-word sentences. Ignore passive voice. Do not ever use a big word when a diminutive one would suffice. Verbs have to be in agreement with their subjects. Prepositions are not expressions to finish sentences with. It is incorrect to ever divide an infinitive. Avoid clichés like the disease. Also, always shun irritating alliteration. Use language that is simple and straight forward. put together a neat summary.

21. Arrangement of information: Each section of the main body should start with an opening sentence and there should be a changeover at the end of the section. Give only valid and powerful arguments to your topic. You may also maintain your arguments with records.

22. Never start in last minute: Always start at right time and give enough time to research work. Leaving everything to the last minute will degrade your paper and spoil your work.

23. Multitasking in research is not good: Doing several things at the same time proves bad habit in case of research activity. Research is an area, where everything has a particular time slot. Divide your research work in parts and do particular part in particular time slot.

24. Never copy others' work: Never copy others' work and give it your name because if evaluator has seen it anywhere you will be in trouble.

25. Take proper rest and food: No matter how many hours you spend for your research activity, if you are not taking care of your health then all your efforts will be in vain. For a quality research, study is must, and this can be done by taking proper rest and food.

26. Go for seminars: Attend seminars if the topic is relevant to your research area. Utilize all your resources.



27. Refresh your mind after intervals: Try to give rest to your mind by listening to soft music or by sleeping in intervals. This will also improve your memory.

28. Make colleagues: Always try to make colleagues. No matter how sharper or intelligent you are, if you make colleagues you can have several ideas, which will be helpful for your research.

29. Think technically: Always think technically. If anything happens, then search its reasons, its benefits, and demerits.

30. Think and then print: When you will go to print your paper, notice that tables are not be split, headings are not detached from their descriptions, and page sequence is maintained.

31. Adding unnecessary information: Do not add unnecessary information, like, I have used MS Excel to draw graph. Do not add irrelevant and inappropriate material. These all will create superfluous. Foreign terminology and phrases are not apropos. One should NEVER take a broad view. Analogy in script is like feathers on a snake. Not at all use a large word when a very small one would be sufficient. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Amplification is a billion times of inferior quality than sarcasm.

32. Never oversimplify everything: To add material in your research paper, never go for oversimplification. This will definitely irritate the evaluator. Be more or less specific. Also too, by no means, ever use rhythmic redundancies. Contractions aren't essential and shouldn't be there used. Comparisons are as terrible as clichés. Give up ampersands and abbreviations, and so on. Remove commas, that are, not necessary. Parenthetical words however should be together with this in commas. Understatement is all the time the complete best way to put onward earth-shaking thoughts. Give a detailed literary review.

33. Report concluded results: Use concluded results. From raw data, filter the results and then conclude your studies based on measurements and observations taken. Significant figures and appropriate number of decimal places should be used. Parenthetical remarks are prohibitive. Proofread carefully at final stage. In the end give outline to your arguments. Spot out perspectives of further study of this subject. Justify your conclusion by at the bottom of them with sufficient justifications and examples.

34. After conclusion: Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print to the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects in your research.

INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

Key points to remember:

- Submit all work in its final form.
- Write your paper in the form, which is presented in the guidelines using the template.
- Please note the criterion for grading the final paper by peer-reviewers.

Final Points:

A purpose of organizing a research paper is to let people to interpret your effort selectively. The journal requires the following sections, submitted in the order listed, each section to start on a new page.

The introduction will be compiled from reference matter and will reflect the design processes or outline of basis that direct you to make study. As you will carry out the process of study, the method and process section will be constructed as like that. The result segment will show related statistics in nearly sequential order and will direct the reviewers next to the similar intellectual paths throughout the data that you took to carry out your study. The discussion section will provide understanding of the data and projections as to the implication of the results. The use of good quality references all through the paper will give the effort trustworthiness by representing an alertness of prior workings.



Writing a research paper is not an easy job no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record keeping are the only means to make straightforward the progression.

General style:

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear

- Adhere to recommended page limits

Mistakes to evade

- Insertion a title at the foot of a page with the subsequent text on the next page
- Separating a table/chart or figure - impound each figure/table to a single page
- Submitting a manuscript with pages out of sequence

In every sections of your document

- Use standard writing style including articles ("a", "the," etc.)
- Keep on paying attention on the research topic of the paper
- Use paragraphs to split each significant point (excluding for the abstract)
- Align the primary line of each section
- Present your points in sound order
- Use present tense to report well accepted
- Use past tense to describe specific results
- Shun familiar wording, don't address the reviewer directly, and don't use slang, slang language, or superlatives
- Shun use of extra pictures - include only those figures essential to presenting results

Title Page:

Choose a revealing title. It should be short. It should not have non-standard acronyms or abbreviations. It should not exceed two printed lines. It should include the name(s) and address (es) of all authors.



Abstract:

The summary should be two hundred words or less. It should briefly and clearly explain the key findings reported in the manuscript-- must have precise statistics. It should not have abnormal acronyms or abbreviations. It should be logical in itself. Shun citing references at this point.

An abstract is a brief distinct paragraph summary of finished work or work in development. In a minute or less a reviewer can be taught the foundation behind the study, common approach to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Yet, use comprehensive sentences and do not let go readability for brevity. You can maintain it succinct by phrasing sentences so that they provide more than lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study, with the subsequent elements in any summary. Try to maintain the initial two items to no more than one ruling each.

- Reason of the study - theory, overall issue, purpose
- Fundamental goal
- To the point depiction of the research
- Consequences, including definite statistics - if the consequences are quantitative in nature, account quantitative data; results of any numerical analysis should be reported
- Significant conclusions or questions that track from the research(es)

Approach:

- Single section, and succinct
- As an outline of job done, it is always written in past tense
- A conceptual should situate on its own, and not submit to any other part of the paper such as a form or table
- Center on shortening results - bound background information to a verdict or two, if completely necessary
- What you account in an abstract must be regular with what you reported in the manuscript
- Exact spelling, clearness of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else

Introduction:

The **Introduction** should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable to comprehend and calculate the purpose of your study without having to submit to other works. The basis for the study should be offered. Give most important references but shun difficult to make a comprehensive appraisal of the topic. In the introduction, describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will have no attention in your result. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here. Following approach can create a valuable beginning:

- Explain the value (significance) of the study
- Shield the model - why did you employ this particular system or method? What is its compensation? You strength remark on its appropriateness from a abstract point of vision as well as point out sensible reasons for using it.
- Present a justification. Status your particular theory (es) or aim(s), and describe the logic that led you to choose them.
- Very for a short time explain the tentative propose and how it skilled the declared objectives.

Approach:

- Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done.
- Sort out your thoughts; manufacture one key point with every section. If you make the four points listed above, you will need a least of four paragraphs.



- Present surroundings information only as desirable in order hold up a situation. The reviewer does not desire to read the whole thing you know about a topic.
- Shape the theory/purpose specifically - do not take a broad view.
- As always, give awareness to spelling, simplicity and correctness of sentences and phrases.

Procedures (Methods and Materials):

This part is supposed to be the easiest to carve if you have good skills. A sound written Procedures segment allows a capable scientist to replacement your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt for the least amount of information that would permit another capable scientist to spare your outcome but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section. When a technique is used that has been well described in another object, mention the specific item describing a way but draw the basic principle while stating the situation. The purpose is to text all particular resources and broad procedures, so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step by step report of the whole thing you did, nor is a methods section a set of orders.

Materials:

- Explain materials individually only if the study is so complex that it saves liberty this way.
- Embrace particular materials, and any tools or provisions that are not frequently found in laboratories.
- Do not take in frequently found.
- If use of a definite type of tools.
- Materials may be reported in a part section or else they may be recognized along with your measures.

Methods:

- Report the method (not particulars of each process that engaged the same methodology)
- Describe the method entirely
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures
- Simplify - details how procedures were completed not how they were exclusively performed on a particular day.
- If well known procedures were used, account the procedure by name, possibly with reference, and that's all.

Approach:

- It is embarrassed or not possible to use vigorous voice when documenting methods with no using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result when script up the methods most authors use third person passive voice.
- Use standard style in this and in every other part of the paper - avoid familiar lists, and use full sentences.

What to keep away from

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings - save it for the argument.
- Leave out information that is immaterial to a third party.

Results:

The principle of a results segment is to present and demonstrate your conclusion. Create this part a entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Carry on to be to the point, by means of statistics and tables, if suitable, to present consequences most efficiently. You must obviously differentiate material that would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matter should not be submitted at all except requested by the instructor.



Content

- Sum up your conclusion in text and demonstrate them, if suitable, with figures and tables.
- In manuscript, explain each of your consequences, point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation an exacting study.
- Explain results of control experiments and comprise remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or in manuscript form.

What to stay away from

- Do not discuss or infer your outcome, report surroundings information, or try to explain anything.
- Not at all, take in raw data or intermediate calculations in a research manuscript.
- Do not present the similar data more than once.
- Manuscript should complement any figures or tables, not duplicate the identical information.
- Never confuse figures with tables - there is a difference.

Approach

- As forever, use past tense when you submit to your results, and put the whole thing in a reasonable order.
- Put figures and tables, appropriately numbered, in order at the end of the report
- If you desire, you may place your figures and tables properly within the text of your results part.

Figures and tables

- If you put figures and tables at the end of the details, make certain that they are visibly distinguished from any attach appendix materials, such as raw facts
- Despite of position, each figure must be numbered one after the other and complete with subtitle
- In spite of position, each table must be titled, numbered one after the other and complete with heading
- All figure and table must be adequately complete that it could situate on its own, divide from text

Discussion:

The Discussion is expected the trickiest segment to write and describe. A lot of papers submitted for journal are discarded based on problems with the Discussion. There is no head of state for how long a argument should be. Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implication of the study. The purpose here is to offer an understanding of your results and hold up for all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of result should be visibly described. Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved with prospect, and let it drop at that.

- Make a decision if each premise is supported, discarded, or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
- Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work
- You may propose future guidelines, such as how the experiment might be personalized to accomplish a new idea.
- Give details all of your remarks as much as possible, focus on mechanisms.
- Make a decision if the tentative design sufficiently addressed the theory, and whether or not it was correctly restricted.
- Try to present substitute explanations if sensible alternatives be present.
- One research will not counter an overall question, so maintain the large picture in mind, where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

Approach:

- When you refer to information, differentiate data generated by your own studies from available information
- Submit to work done by specific persons (including you) in past tense.
- Submit to generally acknowledged facts and main beliefs in present tense.



THE ADMINISTRATION RULES

Please carefully note down following rules and regulation before submitting your Research Paper to Global Journals Inc. (US):

Segment Draft and Final Research Paper: You have to strictly follow the template of research paper. If it is not done your paper may get rejected.

- The **major constraint** is that you must independently make all content, tables, graphs, and facts that are offered in the paper. You must write each part of the paper wholly on your own. The Peer-reviewers need to identify your own perceptives of the concepts in your own terms. NEVER extract straight from any foundation, and never rephrase someone else's analysis.
- Do not give permission to anyone else to "PROOFREAD" your manuscript.
- **Methods to avoid Plagiarism is applied by us on every paper, if found guilty, you will be blacklisted by all of our collaborated research groups, your institution will be informed for this and strict legal actions will be taken immediately.)**
- To guard yourself and others from possible illegal use please do not permit anyone right to use to your paper and files.



CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)
BY GLOBAL JOURNALS INC. (US)

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals Inc. (US).

Topics	Grades		
	A-B	C-D	E-F
<i>Abstract</i>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form Above 200 words	No specific data with ambiguous information Above 250 words
<i>Introduction</i>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<i>Methods and Procedures</i>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<i>Result</i>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<i>Discussion</i>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<i>References</i>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring



INDEX

A

Agarose · 4
Anaesthesia · 17
Arginine · 9

E

Ethidium · 4

I

Immunosorbent · 3

M

Mycoplasma · 1, 2, 3, 5, 7, 8, 24

O

Orthopaedics · 17
Oxacillin · 23, 25, 26, 27, 29, 31, 34

P

Paediatrics · 17
Pleuronemonia · 3
Pneumococci · 27, 29, 30, 32
Pneumoniae · 23, 25, 27, 29, 31, 34
Prothrombin · 11, 13

R

Rifampicin · 23, 25, 26, 27, 29, 31, 34

S

Streptococcus · 23, 24, 25, 26, 27, 29, 30, 31, 32
Symptomatology · 2

T

Thromboembolic · 9, 11, 13



save our planet



Global Journal of Medical Research

Visit us on the Web at www.GlobalJournals.org | www.MedicalResearchJournal.org
or email us at helpdesk@globaljournals.org

ISSN 9755896



© Global Journals